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1 Introduction 
1.1 Genus Hypericum L. 
1.1.1 General information and classification 
Genus Hypericum belongs to family Hypericaceae JUSSIEU and comprises nearly 500 various 
species (Crockett and Robson, 2011), which can be found in almost all parts of the Earth, 
excluding polar regions, deserts and tropical lowlands (Schütt and Schulz, 2007). The earliest 
reference to Hypericum belongs to the II century BC (Robson, 2003) and new species are 
being discovered even today (Ely et al., 2015). 
Family Hypericaceae is well described by (Stevens, 2007) and is divided in three tribes: 
I. Tribe Vismieae CHOISY (1821) 
1. Vismia VAND. – ca. 52 species 
2. Harungana LAMARK – 50 species in 7 groups 
II. Tribe Hypericeae CHOISY (1821) 
3. Hypericum L. – 420 species 
4. Lianthus N. ROBSON – 1 species 
5. Triadenum RAF. – 6 species 
6. Thornea BREEDLOVE & MCCLINTOCK – 2 species 
7. Santomasia N. ROBSON – 1 species 
III. Tribe Cratoxyleae BENTHAM (1862) 
8. Cratoxylum BLUME – 6 species 
9. Eliea CAMBESS. – 1 species 
Several years ago the family Hypericaceae was not defined as independent family, but was 
included in Clusiaceae (Guttiferae). The modern systematic classification of the genus 
Hypericum can be observed from Tab. 1 (§ 1.1.3.3). 
A large number of species in one single genus caused a great need for further and deeper 
classification. Therefore, additional taxonomical units in frames of a genus are used: 
subgenus, sections and series. British botanist Norman Keith Bonner Robson (b. 1928) 
produced a worldwide taxonomic monograph of genus Hypericum between 1977 and 2012 
(Robson, 1977; Robson, 2002; Robson 2003). This work is constantly updated and edited 
through the time, presenting today 30 sections and 6 sub-sections (6a, 9a-e). 
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According to Robson, the division of the genus to sections is based on morphological, 
geographical and phylogenetical principals. All these unite in chemotaxonomy, thus 
emphasizing relative species. Fig. 1 represents connections between the sections of the 
genus. 
 
Fig. 1. Phylogenetic tree of genus Hypericum 
(Sections according to Robson, 1977) (Nürk, 2011) 
A complex mixture of bioactive secondary metabolites in several Hypericum species makes 
them valuable as herbal drugs (Crockett et al., 2005; Mártonfi et al., 2006; Crockett et al., 
2010). A lot of species are used in traditional medicine in different countries all over the 
world. A few examples include: 
 In Europe Hypericum sp. was used since the ancient times. Pedanius Dioscorides 
and Pliny the Elder described its healing and emmenagogue properties (Plinius 
Secundus, 1967). H. perforatum was famous in European herbal medicine (AMR, 
2004; Hahn, 1992), and was first noted as a remedy for melancholy and madness 
in British folk medicine since XVII century (Culpeper, 1652). Until today the genus 
is used in Italian traditional medicine (Idolo et al., 2010). 
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 In Traditional Chinese Medicine (TCM) H. perforatum is known as Guan Ye Lian 
Qiao, originating from “Ben Cao Gang Mu Shi Yi” by Zhao Xue-Min (1765). It is 
used to reduce fever, eliminate toxins, stop bleeding, relief muscles pain and 
treat depression (Chen and Chen, 2012). At least 30 different representatives of 
the genus are being used in the TCM (Zhou et al., 2011). 
 In Middle East species of the genus Hypericum are used in Iranian Traditional 
Medicine for wounds and old sores treatment (Mosaddegh et al., 2012; Ghorbani, 
2005), as well as in Turkey (Altundag and Ozturk, 2011; Cakilioglu et al., 2011) and 
India (Kumar et al., 2007). 
 H. connatum is used in traditional Brazilian medicine as tonic and astringent 
(Correa, 1984). In southern Brazil it is used against oral lesions, frequently caused 
by herpes viruses (Mentz et al., 1997). 
 
1.1.2 Section 9 Hypericum L. 
Section 9 is called Hypericum and comprises 42 species. It is divided in two subsections (Fig. 
2): subsect. 1. Hypericum (widespread) and subsect. 2. Erecta (Japan, Taiwan, eastern China). 
Subsection 1 Hypericum is divided in series 1. Hypericum (species 1-12) and series 2. 
Senanensia (species 13-19, Japan, Korea, China). 
 
Fig. 2. Phylogenetic tree for section 9, subsect. 1, series 1. Simplified. (Robson, 2002) 
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As clearly seen from Fig. 2, Section 9, Subsection 1, Series 1 comprises 12 species, among 
which the most famous member of the family – H. perforatum (Common St. John’s Wort) – 
finds place. This herb is being widely studied and investigated even until today and is 
nowadays successfully used in both traditional and officinal medicine to treat depression 
(Bongiorno and LoGiudice, 2010). In Germany it is prescribed to treat mild to moderate 
depression, especially in children (Dörks et al., 2013; Fegert et al., 2006). However, there are 
data collected in clinical trials which showed, that it was superior to placebo in patients with 
major depression, as effective as standard antidepressants and had fewer side-effects (Linde 
et al., 2008). This is the only Hypericum species, which is approved in several countries for 
medicinal use in humans as a “true medicine” and not as a dietary supplement. Therefore, 
its chemotaxonomical relatives are of a great scientific interest to be well studied, since they 
might be as potent and useful in medicine, as H. perforatum itself or even more. 
1.1.3 Hypericum triquetrifolium TURRA 
Also known as H. crispum L. 
1.1.3.1 Geography and ecology 
H. triquetrifolium was first described by Italian botanist Antonio Turra (1736 – 1797) from 
Vicenza. 
The species is native to mostly eastern Mediterranean region, but can also be found in wild 
nature in Spain (Málaga and Andalucía), Gibraltar, Balearic Islands (Menorca), south France, 
south Italy, Sicily, Malta, Tunisia, Algeria, Libya (Cyrenaica), Montenegro, Albania, Greece 
(mainland and islands), Crete, Cyprus, Turkey, north Syria, Lebanon (coast and lower 
mountains), Israel, Jordan, Egypt (Sinai), Iraq and north-west Iran (Robson, 2002). The herb 
has been naturalised in Australia. (Fig. 3) 
H. triquetrifolium is listed as a “principal” weed in Tunisia and a “common” weed in Lebanon 
(Holm et al., 1979). In these and other countries of the Middle East, it is a weed of cereals, 
orchards, vineyards and waste places. It has established a small infestation in Australia, 
where it is listed as a noxious weed (Parsons and Cuthbertson, 1992). It is poisonous to 
livestock (NGRP, 2002). The plant spreads by both seeds and rhizome fragments following 
cultivation. 
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Fig. 3. Native and naturalized distribution of H. triquetrifolium (Fowler, 2002) 
 
1.1.3.2 Etymology 
The word “Hypericum” is a Latin name of the genus, which most probably derives from 
Greek language. It consists of two parts: “hyper-” (Υπερ, above) and “eikōn” (εἰκών, image) 
(Robson, 2003). The Greek word “Eikōn” is the likely origin of “icon”, which is generally a flat 
panel painting depicting Jesus Christ, Mary, saints and/or angels, which is venerated among 
Orthodox Churches. Therefore, Hypericum might have been the herb, hanging “above the 
image”, protecting it and the house from bad spirits. English common name for the genus is 
St. John’s Wort (“Tutsan” is another one, but rarely used), as well as German – 
Johanniskraut. 
The species name “triquetrifolium” literary means “leaves of three planes”. English common 
names of H. triquetrifolium are: Wavy-leaf St. John’s wort, Curled leaf St. John’s wort, 
Tangled Hypericum or Tumble St. John's-wort. 
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English name “St. John’s Wort” is usually referred to John the Baptist, because the herb 
usually starts blooming at the end of June, when Midsummer or St. John's Day is celebrated 
(Hahn, 1992). 
In Hebrew its scientific name is “Péra mesul’sál’”, which means “curled hypericum”. 
Russian name of the herb is “Zverobóy”, which literary means “he, who kills animals” (from 
zver’ – animal and ubóy – slaughter). This may also explain its poisonousness to livestock (§ 
1.1.3.1). 
1.1.3.3 Botanical and taxonomical description 
H. triquetrifolium is a perennial herb 15-77 cm tall, erect 
to decumbent, with a dense tangle of thin branches, 
glabrous but spotted with small black glands. Sap is 
resinous. It has deep vertical roots and a shallow 
rhizome system from which new shoots are produced. 
Leaves are opposite, sessile, simple, 5-15 mm long, the 
base clasping the stem. Margins of the leaf are wavy, 
undulate, also with small black translucent glands. 
Flowers are yellow, 8-14 mm across, shortly stalked in 
clusters of two to five at the end of branches, with five 
free petals. Stamens are many in three groups. Sepals are 2 mm long, ovate, without glands. 
Fruit is a three-celled dry capsule, 3-5 mm long with numerous small brown seeds (Fig. 4), 
1.5-1.8 mm long, slightly curved, with a pitted surface (Robson, 2002). 
Generally the herb flowers from May to September, however the blossom peak happens 
from mid-June until end of July. 
Photos Fig. 5-8, as well as paintings Fig. 9-10 give better vision of the herb. 
Modern taxonomy of the herb is presented in the following Tab. 1: 
 
 
 
Fig. 4. H. triquetrifolium seed  
(Reed, 1977) 
7 | I n t r o d u c t i o n  
Tab. 1. Scientific classification of H. triquetrifolium TURRA 
Scientific classification 
Domain: Eukaryota 
Kingdom: Plantae 
 Streptophyta 
Subkingdom: Embryophyta 
 Spermatophyta 
Division: Angiosperms (= Magnoliophyta) 
 Eudicots 
Class: Magnoliopsida 
Subclass: Rosids 
Order: Malpighiales 
Family: Hypericaceae 
Subfamily: Hypericoideae 
Tribe: Hypericeae 
Genus: Hypericum 
Section: 9. Hypericum 
Subsection: 1. Hypericum 
Series: 1. Hypericum 
Species: 4. Hypericum triquetrifolium TURRA 
Numbers of section, subsection, series and species – according to Fig. 2. 
 
 
Fig. 5. H. triquetrifolium in wild nature on 4th July 2016, Golan Heights (Israel) 
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Fig. 6. H. triquetrifolium in wild nature on 4th July 2016, Golan Heights (Israel) 
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Fig. 7. Flowers of H. triquetrifolium in wild nature on 4th July 2016, Golan Heights (Israel) 
 
 
Fig. 8. Flowers of H. triquetrifolium in wild nature, 28th August 2012, Golan Heights (Israel) 
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Fig. 9. H. triquetrifolium (Abu-Irmaileh, 1982) Fig. 10. H. triquetrifolium (Edgecombe, 1970) 
 
1.1.3.4 Phytochemistry and pharmacology 
Until today the plant was widely investigated on its essential oil composition. Overall, 109 
compounds were identified. Among them sesquiterpene hydrocarbons (α-humulene, 
cis-calamenene, δ-cadinene, bicyclogermacrene, eremophilene, β-caryophyllene, 
(E)-γ-bisabolene), monoterpene hydrocarbons (α-pinene), oxygenated sesquiterpenes 
(caryophyllene oxide), oxygenated monoterpenes (<1%) and others (Rouis Z. et al., 2012; 
Yuce and Bagci, 2012; Karim et al., 2007). Recent studies of Iranian species proved the 
presence of germacrene-D, β-caryophyllene, δ-cadinene, trans-β-farnesene, α-humulene, 
β-selinene, γ-cadinene and trans-phytol, which were the major constituents of the oil 
(Sajjadi et al., 2015). 
Phenolic compounds are found as well: mostly flavonoids – rutin (= quercetin-3-O-α-L-
rhamnopyranosyl-(1→6)-β-D-glucopyranoside), hyperoside (= quercetin-3-O-galactoside), 
apigetrin (= apigenin-7-O-glucoside), kaempferol, quercitrin, quercetin and amentoflavone 
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(Cirak et al., 2011), and also I3, II8-biapigenin, astragalin (= kaempferol-3-O-glucoside), 
(-)-epicatechin (Conforti et al., 2002). Confirmed are naphthodianthrones (so called 
hypericins): hypericin, pseudohypericin, protohypericin and protopseudohypericin, as well as 
4 acylphloroglucinols: hyperforin and adhyperforin (Alali and Tawaha, 2009) and most 
recently discovered adhyperfirin and hyperibine J (Fig. 11) (Mitsopoulou et al., 2015). Fatty 
acids, namely α-linolenic acid (C18:3), linoleic acid (C18:2), oleic acid (C18:1), palmitic acid 
(C16:0) and stearidonic acid (C18:4) were isolated from Tunisian resources of H. 
triquetrifolium (Hosni et al., 2007). 
 
Fig. 11. Acylphloroglucinols isolated from H. triquetrifolium TURRA. 
Hypericins are one of the principle components in many species of the genus Hypericum. 
They are responsible for large number of biological effects: antimicrobial (García et al., 
2015), antiviral (Hudson et al., 1991) and antiretroviral (Stevenson and Lenard, 1993), stress-
relieving and antidepressant effects (Wang et al., 2010) and many others. An exhaustive and 
comprehensive review on the biological effects of hypericins can be found in (Karioti and 
Bilia, 2010). 
Extensive literature review revealed, that the only one non-Hypericum herb known today to 
accumulate hypericin as well as pseudohypericin, is Haronga or Harungana 
madagascariensis LAMARCK EX POIRET from the same family Hypericaceae (tribe Vismieae, 
§ 1.1.1). These compounds were extracted from the herb’s leaves (Fisel et al., 1966; Hölzl 
und Petersen, 2003). 
H. triquetrifolium is believed to be potent against retroviruses, because of the high content 
of naphthodianthrones (Stojanovic et al., 2013). Essential oil of collected in Tunisia 
H. triquetrifolium shows “good antibacterial”, “promising antifungal”, “significant 
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anticandidal” and low cytotoxic effect and did not show any antiviral activity against 
Coxsackievirus B3 (Rouis et al., 2013). Israeli study suggests that the herb probably exerts 
anti-inflammatory effects through the suppression of TNF-α and iNOS expressions (Saad at 
al., 2011). In Sulforhodamine B assay the I3, II8-biapigenin isolated from the methanolic 
extract exhibited strong cytotoxic activity with a certain degree of selectivity against 
different cell types (Conforti et al., 2007). Plant extract shows promising antimicrobial 
activity (Al-Bakri and Afifi, 2007). Greek scientists observed “the highest cytotoxic activity” 
on brine shrimps (LC50 = 22 mg/mL) and good antioxidant activity in vitro (Couladis et al., 
2002). Anti-inflammatory effect on rats by H. triquetrifolium extract was also shown (Ozturk 
et al., 2002). Lyophilized extract exhibits antinociceptive activity in mice (Apaydin et al., 
1999). 
1.1.4 Acylphloroglucinols 
Acylphloroglucinols form a diverse class of secondary metabolites, which can be found in 
various plants, marine and microorganisms all around the Earth. They possess a diverse 
structure, as well as strong and highly versatile biological activity. There are almost 1000 
unique compounds known and more are being elucidated and described every year (Singh 
and Bharate, 2006). 
For genus Hypericum more than 300 phloroglucinols are known (Schmidt and Heilmann, 
2013). Probably the most famous of them is hyperforin (Fig. 11), found in Hypericum 
perforatum in larger amounts, which is widely used today in officinal medicine. It has also 
been found in other Hypericum species. 
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1.1.4.1 Biosynthesis of acylphloroglucinols 
Phloroglucinols are polyketides which derive from the acetate-malonate pathway. As such, a 
CoA-activated aromatic or aliphatic starter acid (acetyl-, propionyl-, butyryl-, isobutyryl-, 2-
methylbutyryl-CoA) reacts with 3 molecules of malonyl-CoA, which serves as an extender 
acid (Avato, 2005). This intermolecular decarboxylative Claisen condensation is catalyzed by 
an enzyme called polyketide synthase (Type III PKS). Via the formation of an intermediate 
polyketide, which cyclise through the intramolecular Dieckmann condensation, an 
acylphloroglucinol backbone is built. It undergoes then a subsequent prenylation: a special 
enzyme prenyltransferase (PT) catalyses the reaction of addition of dimethylallyl 
pyrophosphate (DMAPP) to the main molecule. Thus a (poly-) prenylated acylphloroglucinol 
is formed. Several prenyl-/geranyl- chains may also cyclise, forming bi- or polycyclic 
derivatives. A proposed acylphloroglucinol biosynthesis pathway on example of hyperforin 
was described by working group of Prof. Dr. Ludger Beerhues (Institute for Pharmaceutical 
Biology, University of Braunschweig, Germany) and is shown on Fig. 12 below. 
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Fig. 12. Proposed biosynthesis of hyperforin (Beerhues, 2006), modified. (Klingauf et al., 
2005; Dakanali and Theodorakis, 2011) 
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DMAPP biosynthesis simplified scheme may be observed from Fig. 13. In nature two possible 
biosynthesis pathways exist: via MVA (primarily in plants and in rare insects) or via 
DOXP/MEP pathway (characteristic for algae, cyanobacteria, as well as for Mycobacterium 
tuberculosis and malaria parasites). Both pathways result in two isomers: DMAPP or IPP. The 
latter is relatively un-reactive, that is why a special enzyme IPP-isomerase turns it into a 
more-reactive electrophile DMAPP, which, in turn, plays important role in prenylated 
acylphloroglucinols biosynthesis (Fig. 12). 
 
Fig. 13. Mevalonate and non-mevalonate pathways 
of DMAPP’s biosynthesis (Zurbriggen et al., 2012). Simplified, modified. 
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1.1.4.2 Structural diversity and classification of acylphloroglucinols 
Great number and broad structural variety of acylphloroglucinols makes it really difficult to 
present a clear and unambiguous classification. Two big reviews have been prepared and 
help better understand the entire depth of the question. The first one by (Singh and Bharate, 
2006) describes phloroglucinols, discovered not only in plants, but also in other organisms. 
The second one by (Schmidt and Heilmann, 2013) focuses on acylphloroglucinols isolated 
from Hypericum. And even in the latter case, dedicated to the herbs of only one genus, the 
classification is not so easy and unequivocal. 
Essentially the compounds can be divided into mono-, bi-, tri-, tetrameric, etc. They can also 
be mono-, bi- and polycyclic (MPAPs – monocyclic polyprenylated acylphloroglucinols; 
BPAPs – bicyclic polyprenylated acylphloroglucinols; PPAPs – polycyclic polyprenylated 
acylphloroglucinols). They can also be C- or O- prenylated or geranylated, methylated, 
methoxylated, with sugars, with aliphatic or aromatic starter acid. Isoprene and geranyl 
chains can cyclise in ortho- or para- position to starter acid and thus form either 5-ring 
(furan) or 6-ring (pyran) derivatives (Fig. 16). Even epoxy and hemiacetal phloroglucinols do 
exist. Of course, all these possibilities may be combined together and build a very 
complicated single compound (Fig. 14). 
 
i 
 
ii 
 
iii 
 
iv 
 
v 
 
vi 
i – C- and O-methylated, non-prenylated. From H. beanii (Shiu and Gibbons, 2006) 
ii – O-prenylated, C-methylated. From H. calycinum (Decosterd et al., 1991) 
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iii – O-glycoside, C-methylated. From H. japonicum (Wu et al., 1998) 
iv – C-prenylated with 5-ring adduct. From H. ascyron (Hashida, 2008) and H. riparium (Tala, 
2015) 
v – C-prenylated, spiro-condenced. From H. henryi (Yang, 2015b) 
vi – Dimeric, C-prenylated, C-methylated. From H. uliginosum (Parker and Johnson, 1968) 
 
Fig. 14. Examples of MPAPs’ structural diversity. 
Structure diversity not only determines herb’s biological activity, but is also genetically 
determined and therefore plays an important role in its chemotaxonomical classification. 
Herbs from each section of the genus comprise typical types of phloroglucinols and let 
Norman Robson inter alia classify the plants respectively (Robson 1977; Robson 2002). As an 
example, herbs from sections 14 and 15 accumulate only acylphloroglucinols, which can be 
described as monocyclic O-glycosides, while section 10 has only O-prenylated or geranylated 
compounds; and species from section 13 form polycyclic compounds of undefined type. As 
opposed to described sections, sections 3, 9 and 9c are rich in quite various types and 
cannot be characterised by one specific acylphloroglucinol type. 
Principal classification of monomeric bi- and polycyclic acylphloroglucinols were proposed by 
(Dakanali and Theodorakis, 2011). Scientists define four classes, namely A, B(I), B(II) and C. 
 
Fig. 15. Classification of BPAPs and PPAPs (Dakanali and Theodorakis, 2011). Simplified. 
Fig. 15 clearly shows the difference between compounds of types A, B(I) and C, which are 
characterized by a highly oxygenated bicyclo[3.3.1]nonane-2,4,9-trione, while type B(II) is 
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based on bicycle[3.2.1]octane-2,4,8-trione skeleton. Each skeleton can be prenylated or 
geranylated, as well as the prenyl/geranyl chains may cyclize to form tri- or polycyclic 
compounds of furano-, chroman-, chromene- type, etc. Possible cyclization on example of A-
type can be observed from Fig. 16. 
 
Fig. 16. Possible cyclization and formation of furano- or pyrano- PPAPs derivatives on 
example of Type-A acylphloroglucinol. Simplified. (Schmidt and Heilmann, 2013) 
Presented in Fig. 16 possible biosynthesis processes let one classify the compounds not only 
according to their scaffolds, but also in accordance with their additional customizations. 
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1.1.4.3 Biological properties of acylphloroglucinols 
Almost all newly discovered acylphloroglucinols are being studied in vitro on their biological 
and pharmacological effects. These do vary a lot and present a vast palette of different 
kinds. Most common effects and activities include: 
 antidepressant (Stein et al., 2012; Jensen et al., 2001) 
 antiproliferative (Schmidt et al., 2012; Pinhatti et al., 2013; Sun et al., 2014) 
 cytotoxic (Chen et al., 2011; Liu et al., 2013) 
 antinociceptive (Stolz et al., 2014) 
 antioxidative (Wu et al., 2008; Alfaro et al., 2014; Sun et al., 2014) 
 larvicidal (Mitsopoulou et al., 2014) 
 antiangiogenic (Schmidt, 2013) 
 antimicrobial (Tanaka et al., 2011) 
 anti-inflammatory (Crockett et al., 2008) 
 analgesic (Stolz et al., 2016) 
 antiviral (Piccinelli et al., 2005; Hu et al., 2016) 
 anti-HIV (Fobofou et al., 2015) 
 neuroprotective (Gao et al., 2016) 
 antifungal (Tanaka et al., 2008) 
 cyclooxygenase-1 and -2 inhibition (Henry et al., 2009) and many others. 
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1.2 Neurodegenerative diseases 
1.2.1 Introduction 
EU Joint Programme – Neurodegenerative Disease Research (JPND Research) defines 
neurodegenerative disease as an umbrella term for a range of conditions which primarily 
affect the neurons in the human brain. 
Neurodegenerative disorders (NDs) are incurable today, although neurons do replicate and 
differentiate in mammalian brain during the whole life (Danielson et al., 2016; Zhao et al., 
2008; Dranovsky et al., 2011). Problems caused may affect movement (ataxias) or mental 
health (dementias). Cognitive abilities, such as memory or decision making are also harmed. 
Number of NDs is great. Among most common diseases are: 
 Alzheimer’s disease (AD) 
 Parkinson’s disease 
 Huntington’s disease 
 amyotrophic lateral sclerosis (ALS) 
 Creutzfeldt-Jakob disease (CJD) 
 primary progressive aphasia 
 progressive supranuclear palsy 
 and many others. 
NDs are very important issue especially of the western world; it is being taken serious care in 
all developed countries. In both EU and USA there are numerous institutes and funds, which 
closely cooperate in order to discover a secure and effective medicine for NDs. To name a 
few, EuroPa is the European Cooperative Network for Research, Diagnosis and Therapy of 
Parkinson's Disease. European Huntington's disease Network (EHDN), European and Allied 
Countries Collaborative Study Group of CJD (EUROCJD) with local offices in the UK, Spain, 
France, Italy, Canada and USA, as well as US National Institute of Neurological Disorders and 
Stroke – are only a few examples of how broad and deep is the research on NDs conducted 
today. 
According to EuroStat, the rise of the median age of population in 28 EU countries from 2004 
to 2014 composes ca. 7% (39.5 years in 2004 versus 42.2 years in 2014). These data show the 
population doesn’t get younger as time passes and with the development of medicinal 
technology, preventive diagnostics and medication and rise of overall life quality, there will 
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be more aged people, than it would have been 10 or 20 years ago. Age, i.e. changes 
undergoing in a human organism with the flow of time, are a part of not till the end known 
reasons, leading to NDs (Hung et al., 2010). 
Public health department of European Commission quotes the data, calculated by (Olesen et 
al., 2012), which say that total European cost of brain disorders in 2010 estimated € 798 
billion, affecting more than a third of the continental population. Compared to year 2004, 
when 127 million adults were affected by disorders of the brain in the EU member states, 
Iceland, Norway and Switzerland € 386 billion were spent (Andlin-Sobocki et al., 2005). A 
doubling of costs in 6 years shows significant increase of the patients, as well as a strong 
growing necessity to obtain an efficient preventive drug. 
Constant works on AD costs estimation and its’ influence on the state’s economy are 
performed in the USA (Meek et al., 1998), China (Keogh-Brown et al., 2015), Sweden 
(Åkerborg et al., 2016), Czech Republic (Marešová et al., 2015) and other countries. The 
inferences are unfavourable: expenses are growing at full pelt. 
All the facts, mentioned above prove the need to further and deeper investigate these group 
of diseases, broaden research and discovering a potent and safe medicines to prevent and 
treat the pathological conditions. 
1.2.2 Aetiology of neurodegenerative disorders 
When talking about NDs, it is usually meant that CNS, i.e. brain is hurt. The great variety of 
illnesses does not, however, have the same origin and may appear through a number of 
different factors, processes and conditions. 
The most widespread disorder is AD, followed by Parkinson's (Elbaz et al., 2016). A bit less 
common, but not less important include Huntington's, CJD, ALS, epilepsy, migraine and 
chronic pain and many others. NDs may have common whence, as well as their aetiology 
might be very much different and is not well known and clear until today. For example, one 
most recent study even proposes, that AD is not a single disease, but a group of diseases, 
which have absolute different aetiology (Ben‐Gedalya et al., 2015). Still there are a lot of 
argues and discussions on this matter and the consensus is far away. 
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While a lot of researches are conducted all over the world, different scientific groups name 
different factors as the cause of concrete disease. In short, the aetiology is very complicated 
and not always unequivocal. In the following Tab. 2 an overview with a few examples is 
presented. Both similarities and differences in developing of these pathologic states can be 
noted. 
Tab. 2. Overview of NDs aetiologies. 
NDs Cause Source 
Alzheimer’s 
oxidative stress 
Cacciapuoti, 2016 
Moulton and Yang, 
2012 
mitochondrial dysfunction, accumulation of 
abnormally folded Aβ protein, which build senile 
plaques in brain 
Hashimoto et al., 2003 
genetic predisposition 
Wilson et al., 2011 
Gatz et al., 2006 
cholinergic hypothesis: reduced production of 
acetylcholine 
Francis et al., 1999 
hyperphosphorylated tau protein connects to 
other tau proteins and forms neurofibrillary tangle 
inside nerve cells – its structure is being damaged 
and the cell dies 
Goedert et al., 1991 
Iqbal et al., 2005 
herpes simplex virus Type I 
Itzhaki and Wozniak, 
2008 
metals like Cu, Zn, Al, Fe are being discussed to be 
one of the initiators of the disease 
Brewer, 2012 
lack of sleep Mander et al., 2015 
age-related myelin breakdown in the brain Bartzokis, 2011 
obesity Ballard et al., 2011 
smoking Cataldo et al., 2010 
less daily computer use Silbert et al., 2016 
environment and ecology 
Moulton and Yang, 
2012 
head injuries, depression, hypertention Burns and Iliffe, 2009 
1) mutations: amino acid proline is being replaced 
in both prions and in presenilin 1 protein. Its 
functional interaction with chaperone protein 
cyclophilin B is impaired. Presenilin 1 fails to fold 
properly. Attenuation of γ‐secretase activity and 
impairment of mitochondrial distribution and 
function. 
2) aging 
Ben‐Gedalya et al., 2015 
transmissible Alzheimer's theory, prions Abbott, 2016 
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Parkinson’s accumulation of iron 
Medeiros et al., 2016 increased production of ROS and RNS 
inflammatory markers 
oxidative stress Cacciapuoti, 2016 
1) Aβ and  α -synuclein oligomers might damage 
the mitochondrial membrane 
2) mitochondrial damage might promote Aβ and 
α-synuclein aggregation 
3) Aβ  oligomers and α-synuclein might interact in 
disturbing mitochondrial function 
Hashimoto et al., 2003 
influence of the surroundings, ecology Noyce et al., 2012 
genetic factors (in ca. 15% of patients) Samii et al., 2004 
Huntington’s accumulation of misfolded proteins in neuronal 
cytosol and nuclei 
Cummings and Zoghbi, 
2000; Muchowski, 2002 
genetic mutation in HTT gene on the short arm of 
chromosome 4; cytosine-adenine-guanine (CAG) 
trinucleotide repeat. 
Walker, 2007 
autosomal dominant inheritance 
ALS genetics (5-10% of cases are directly inherited 
from parents): defect on chromosome 21, which 
codes for superoxide dismutase 
Kiernan et al., 2011 
Battistini et al., 2010 
90% are classified as having sporadic disease but 
how do people get ill is still not clear 
Kiernan et al., 2011 
oxidative stress Cacciapuoti, 2016 
people with ASL have higher levels of glutamate in 
their serum and spinal fluid, but it is not the sole 
cause of the disease 
Al-Chalabi and Leigh, 2000 
DLB mitochondrial dysfunction and abnormal 
accumulation of α-synuclein in neuronal cell 
bodies, axons, and synapses 
Hashimoto et al., 2003 
CJD 1) Alzheimer-type Aβ pathology, prions 
2) transmissible theory 
Frontzek, 2016 
aging Ben‐Gedalya et al., 2015 
 
As clearly seen from Tab. 2 above, oxidative stress in general is one of the most important 
factors, leading to different NDs. It can be expressed in several ways, e.g. through elevation 
of ROS levels or damaging important cellular macromolecules like lipids, proteins and DNA 
(Cacciapuoti, 2016). 
Medication therapy of the NDs is debatable. For example, as of April 2016 there are 408 
open clinical trials (in comparison to 315 cases in 2014) to understand the mechanisms and 
evaluate drugs for AD treatment. These data are provided by online service clinicaltrials.gov, 
which is an agency of the US National Institutes of Health. Tens of approaches are being 
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tested, including among others immunotherapy to Aβ (Dodel et al., 2010), use of statins 
(Whitfield, 2007), antibiotics (Loeb et al., 2004), antiviral agents (Itzhaki and Wozniak, 2008) 
and even intranasal insulin (Freiherr et al., 2013; Vandal et al., 2014). Tetrahydrocannabinol 
(THC) was also asserted to inhibit AChE and therefore reduce Aβ plaque formation (Eubanks 
et al., 2006). 
Most recent successful discoveries. Some of the researches are fruitful and already do show 
interesting results. An Australian study proposes not yet a full cure, but significant 
improvement – AD patients may restore their memory by removing Aβ proteins with the 
help of scanning ultrasound (Leinenga and Götz, 2015). Scientists from MIT under the 
supervision of the Nobel Prize-winning Professor Susumu Tonegawa propose the memory 
retrieval by activating engram cells in mouse models of early stages of AD (Roy et al., 2016). 
Working groups from UCSF Gladstone Institutes in San Francisco reveals a mechanism of tau 
protein toxicity and memory loss in AD. Also involved is a memory-associated KIdney/BRAin 
(KIBRA) protein. This discovery may also help to restore memory in AD patients (Tracy et al., 
2016). 
Working group of Prof. Fischer from the Bar-Ilan University (Ramat-Gan, Israel) reports 
successful treatments of AD causing factors – oxidative stress and Aβ – first in culture, later 
in mice (Danino et al., 2015), however it is still too early to talk about treating the AD in all 
the patients. 
The Buck Institute (California, USA) research showed that vitamin D3 induces expression of 
SKN-1 target gene, influences the proteins insolubility and therefore prevents toxicity, 
caused by human Aβ (Mark et al., 2016). That is why it can also be used as an effective 
solution to treat NDs. 
Worldwide famous Ice Bucket Challenge flash mob, which went around the Earth mainly in 
August 2014, resulted in collecting more than 100 million US dollars from donations. This 
helped scientists from 38 various research institutes worldwide in discovering that single 
mutations in NEK1 gene are responsible for developing the ALS (Kenna et al., 2016). Further 
genome studies identify C21orf2 as an additional gene associated with ALS risk. Besides that 
MOBP and SCFD1 are also named as risk loci (van Rheenen et al., 2016). 
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1.2.3 Glutamate-induced neurotoxicity 
Not the last role in causing an oxidative stress belongs to glutamate 
(Glu), an important and abundant excitatory neurotransmitter in 
CNS (Meldrum, 2000; Zhang et al., 2016). Glutamate or glutamic 
acid (Fig. 17) is an α-amino acid, used in the biosynthesis of 
proteins. It is non-essential in humans, which means the body can 
synthesize it. Glu is contributing to normal neural transmission, development, 
differentiation, and plasticity (Kritis et al., 2015). It is involved in cognition, i.e. memory and 
learning (Yang et al., 2011). At the same time pathologically elevated levels of glutamic acid 
are harmful for the CNS and may incur toxicity and oxidative stress, which in turn develop 
various acute and chronic diseases of the brain, including ischemia and NDs, like Parkinson’s 
or AD (Lipton and Rosenberg, 1994; Mattson and Magnus, 2006). 
Glutamate expresses its toxicity in 2 possible pathways: 
1) NMDA-mediated excitotoxicity. Ionotropic glutamate receptors (i.e. NMDA-, AMPA- or 
kainate receptors) mediate the excitotoxicity through Ca2+ influx and ROS concentration 
during the cell death. Glutamate activates the receptor, Ca2+ flows into the cell: its high 
concentrations in cytoplasm provokes arachidonic acid cascade, which results in NO, O2• 
radicals’ production (Choi, 1988; Coyle and Puttfarcken, 1993) and release of lysosomal 
enzymes. Excitotoxicity is associated with most common NDs, as well as with stroke and 
traumatic brain injury (Kritis et al., 2015). 
2) Oxytosis. Oxidative glutamate toxicity is not mediated by receptors (e.g. in cells, which 
do not have any NMDA receptors). It is initiated by high concentrations of Glu in the 
intercellular space (Fig. 18). As such, Glu/cystine antiporter system in cell membrane is 
being blocked. It results in cystine (oxidized dimer of cysteine) uptake inhibition, lowered 
levels of cysteine and glutathione (GSH) synthesis suppression. Cysteine is the rate-
limiting factor in cellular GSH biosynthesis. GSH is also an important intracellular 
antioxidant, preventing cells from damage, caused by ROS (Pompella et al., 2003). 
Since the GSH level in the cell is low, ROS production is mild on initial stages (5-10 fold 
increase), followed by an explosive boost (200-400 fold increase) from mitochondria with 
Fig. 17. Glutamic acid 
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the course of time. The cell undergoes an oxidative stress (Murphy et al., 1989; Tan et 
al., 1998b). 
Second increase of ROS levels causes 12-LOX activation and consequently sGC, which is 
responsible for conversion of GTP into cGMP (Tan et al., 2001). The latter activates the 
cGMP-dependent Ca2+ channels. Ca2+ flows drastically into the cell and its accumulation 
in cytoplasm is a major downstream event in glutamate-induced cell death cascade (Tan 
et al., 1998a). 
Ca2+ ions are deleterious for the cells, since they lead to disturbance of the mitochondrial 
membrane potential, which in turn leads to ATP synthesis inhibition. Ca2+ also disturbs 
electron transport chain – this directs to ROS increasing production. 
Further studies of oxytosis were continued by (Fukui et al., 2009). Early stages (8-12 h) 
are characterised by necrosis, followed by apoptosis afterwards (16-24 h). The latter is 
defined by release of AIF from damaged mitochondria (it catalyses DNA fragmentation), 
activation of MAPK cascades and other processes. Important apoptosis parameters, e.g. 
cytochrome C release or depolarisation of mitochondrial membrane do not, however, 
happen (Tan et al., 2001), thus the word “oxytosis” describes the cascade better, than 
regular necrosis or apoptosis (Kling, 2015). 
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Fig. 18. Glutamate-induced toxicity in HT-22 cells, proposed by (Fukui et al., 2009; Tan et al., 
1998a; Maher and Schubert, 2000). 
There are several defence mechanisms exerted by a number of secondary metabolites of 
natural origin. A study by (Ishige et al., 2001) confirms that flavonoids protect the cell from 
an oxidative stress via three different mechanisms: 
 preventing the GSH decrease (quercetin, fisetin) 
 blocking ROS production (quercetin, vitamin E, kaempferol, galangin, luteolin) 
 inhibiting  Ca2+ influx (flavonol) 
Important discovery of this work is that quercetin along with fisetin increase GSH levels in 
HT-22 cells both in the presence and absence of Glu. This allows the use of quercetin as 
positive control in Glu-induced toxicity tests on HT-22 cells, which do not possess NMDA 
receptors (Zaulyanov et al., 1999), so the assays conducted with them show oxytosis toxicity 
and not excitotoxicity. 
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1.2.4 Role of Hypericum in treating NDs 
Hypericum is being widely studied to medicate NDs. Standardized extract enriched in 
hyperforin from H. perforatum along with quercetin were suggested to provide better 
therapeutic advantage for the management of Parkinson’s disease (Gómez del Rio et al., 
2013). Phenolic compounds (quercetin, kaempferol and biapigenin) isolated from the same 
herb may be used in prevention of Parkinson’s disease (Vieira et al., 2011). Yet another 
recent study confirms the feasibility of using H. perforatum and its main constituent 
hyperforin in AD therapy (Griffith et al., 2016). Complex plant extract from H. perforatum 
may restore or improve microglial viability and attenuate amyloid-β (Aβ) mediated toxicity in 
AD (Kraus et al., 2007), which is closely connected to the following scientific investigation. 
Acylphloroglucinol hyperforin itself also influences the Aβ-induced neurotoxicity and may be 
used a putative therapeutic agent to fight the AD (Dinamarca et al., 2006). 
Tetrahydrohyperforin, a semi-synthetic hyperforin derivative, generates neuroprotective 
effects and prevents memory loss in double transgenic mice modelling AD (Montecinos-Oliva 
et al., 2015). The same study proposes that tetrahydrohyperforin is an agonist of the 
TRPC3/6/7 subfamily of channels in cytomembrane. The compound may increase Ca2+ 
concentrations in the cell (§ 1.2.3) and generates stronger synaptic responses, which might 
be compensating the effects of amyloid-β oligomers. Aβ is a peptide of 39–42 amino acids 
which is involved in AD as the main component of the amyloid plaques found in the brains of 
Alzheimer patients (Ittner and Götz, 2011; Nussbaum et al., 2013; LaFerla et al., 2007). Since 
hyperforin selectively activates TRCP6 channels while TRPC1/3/4/5 channels remained 
unaffected (Leuner et al., 2007), TRPC6 is the most likely candidate to be targeted by 
tetrahydrohyperforin. However, the lack of an atomic resolution structure of any TRPC 
channel doesn’t let any rational drug design for these channels at the moment. 
Almost all studies focus on and represent mostly one and the most famous member of the 
genus, i.e. H. perforatum, which makes other Hypericum species interesting for investigation 
and comparison, whether they can also be potent in treating any NDs. 
However, some rare studies on other species exist. Research on neurotoxicity and 
neuroprotection of organically synthesized acylphloroglucinols (Sun et al., 2014) in 
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compination with derivatives isolated from H. empetrifolium (Schmidt, 2013) was conducted 
on HT-22 cells in Glu-induced toxicity assays by (Pitzl et al., 2015). 
Chinese scientists elucidated polycyclic prenylated acylphloroglucinols from Hypericum 
scabrum and proved their neuroprotective effects on Glu-induced toxicity in SK-N-SH cells. 
Investigated compounds exhibited significant neuroprotection at 10 μM (Gao et al., 2016). 
Most recent study focuses on Hypericum uralum from Tibet and northwest of Yunnan 
Province, PRC. Isolated from this herb 1,9-seco-BPAPs hyperuralones C and D were examined 
against acetylcholinesterase (AChE) using the Ellman method (Ellman et al., 1961) and 
exhibited moderate AChE inhibitory activities (Zhang et al., 2015). 
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1.3 Aim of the present work 
1.3.1 Isolation of acylphloroglucinols from H. triquetrifolium 
Being wide and successfully used for ages in traditional medicine by different peoples in its 
native Mediterranean region, H. triquetrifolium looks very promising to be scientifically 
investigated and deeper studied. Until now only 4 acylphloroglucinol derivatives were 
isolated, therefore, exploring the herb’s secondary metabolites is of a great interest. 
Acylphloroglucinols possess strong and highly diverse biological activity – they are of a great 
medicinal importance. Moreover, the isolated acylphloroglucinols may prove and confirm 
chemotaxonomic connections and family ties in frames of the species and section 9 
Hypericum. 
With the use of NMR-guided fractionating strategy acylphloroglucinol derivatives are to be 
isolated, their structure is to be elucidated and confirmed with MS. Newly discovered 
substances should be characterised by their physico-chemical constants, such as UV 
wavelength maxima, CD spectroscopy and specific rotation. 
1.3.2 Testing the isolated substances on neuroprotection 
Almost all the acylphloroglucinol derivatives isolated from Hypericum species show diverse 
and strong bioactivity in vitro (Schmidt, 2013; Zhou et al., 2014; Fobofou et al., 2015; Dos 
Santos et al., 2015). Taking into consideration close relative phylogenetic bonds between H. 
triquetrifolium and H. perforatum, as well as the wide and successful use of the later (§ 
1.1.2), studying the influence of the isolated acylphloroglucinols on the CNS, i.e. 
neuroprotection assay is of a great interest and importance. 
Further recent pharmacological investigations on medicinal botanicals prove high potential 
of nature secondary metabolites in treating Glu-caused oxidative stress in HT-22 cells (Lee et 
al., 2015; Dos Santos et al., 2016). 
A study of neuroprotection of organically synthesised phloroglucinols was conducted at the 
University of Regensburg. The work showed that the investigated substances, especially 
those with catechol structure, possess neuroprotective properties (Pitzl et al., 2015). 
Evaluating the pharmacological activity of acylphloroglucinols with another structure, i.e. 
PPAPs in particular and comparing the studies’ data would be of a great interest.
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2 Materials and methods 
2.1 Phytochemical methods 
All the glassware, devices and software (Tab. 3), solvents and chemicals (Tab. 4), as well as 
phytochemical methods described in this chapter refer to and were used for the extraction 
of the plant, isolation of pure compounds, their analysis and characterisation. 
2.1.1 Devices, vessels and software 
Table 3. Glassware, devices and software for the phytochemical methods. 
Device Model Manufacturer 
Analytical weights R 160 P Sartorius, Göttingen 
CD Spectropolarimeter J-710 Jasco, Groß-Umstadt 
CPC 
SPOT centrifugal partition 
chromatography 
Armen, Saint-Ave (FR) 
Pump: 515 HPLC Waters (US) 
Fractions collector: 2211 Superrac 
Racks: Type B2 
LKB, Bromma (SE) 
Flash Chromatography 
Spot Liquid Chromatography Flash 
Armen Glider Flash V 2.3 (Software) 
Armen, Saint-Ave (FR) 
Glass-frit-adapter 
top female Joint: ST/NS 29/32 
bottom male Joint: ST/NS 29/32 
self-made at the University’s 
blowing shop, Regensburg 
Glass pipettes 
0.1 mL, 0.2 mL, 0.5 mL, 1 mL, 2 mL, 
5 mL, 10 mL, 20 mL 
Brand, Wertheim 
HPLC semi-preparative 
ProStar 
410 (Autosampler) 
210 (Both pumps) 
335 (DAD) 
701 (Fractions collector) 
Galaxie 1.9.302.952 (Software) 
Varian, Darmstadt 
HPLC syringe 
for manual injection 
Gas Tight Syringe 2.5 mL 
Cat. no. 549-0537 
VWR, manufactured for 
VWR-Leuven, Belgium in (JP) 
Laboratory film 
Parafilm® “M” 4 in. x 125 ft. roll 
Cat. no. PM996 
Bemis, Neenah, WI (US) 
Mass spectrometer UPLC-HRMS: Q-TOF 6540 UHD Agilent, Darmstadt 
Measuring flasks 5 mL, 10 mL, 25 mL Brand, Wertheim 
Measuring cylinder 25-500 mL Brand, Wertheim 
Mill Yellow line A10 IKA-Werke, Staufen 
NMR tubes 507HP Norell, Landisville (US) 
NMR spectrometer 
Avance 300 
Bruker, Ettlingen Avance 400 
Avance III 600 
NMR software TopSpin 3.2 Bruker, Ettlingen 
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Painting software ChemDraw Professional 15.0 Perkin Elmer, Waltham (US) 
Pasteur glass pipettes, 
disposable 
150 mm (Cat. no. 612-1701) 
230 mm (Cat. no. 612-1702) 
VWR, Fontenay-sous-Bois 
(FR) 
Polarimeter P8000-PT Krüss, Hamburg 
Precision balances LE4202S Sartorius, Göttingen 
Quartz cuvettes QS; 10,00 mm Hellma, Müllheim 
Rotation evaporator Laborta 4003-control Heidolph, Schwabach 
Round-bottom flask 100, 250, 500 and 1000 mL 
Schott Duran, 
Wertheim/Main 
Snap-cap glass vial 
5 mL, 40x20 mm, 18 mm snap cap 
Cat. no. 548-0555 
VWR, Darmstadt 
Syringe 
1 mL Norm-Ject® tuberculin Luer 
Cat. no. 4010-200V0 
Henke Sass Wolf, Tuttlingen 
10 mL (12 mL) Norm-Ject® Luer 
Lot 4A27048 
Henke Sass Wolf, Tuttlingen 
Syringe filter Perfect Flow®, pore size 0.2 µm Wicom, Maienfeld 
UV spectrophotometer 
Cary 50 Scan 
Cary WinUV 3.00(182) (Software) 
Varian, Darmstadt 
Ultra-sound water bath Ultrasonic cleaner VWR, Darmstadt 
 
2.1.2 Chemicals and solvents 
Table 4. Chemicals and solvents used in phytochemical methods 
 Specification and quality mark Manufacturer 
Acetonitrile 
gradient grade for liquid chromatography 
(LiChrosolv®) 
Cat. no. 1.00030.2500 
Merck, Darmstadt 
Acetic acid 
100% anhydrous for analysis (glacial) 
Cat. no. 1.00063.2500 
Merck, Darmstadt 
p-Anisaldehyde 
4-Methoxybenzaldehyde 98% 
Cat. no. A88107 
Aldrich, Steinheim 
Chloroform-d1 
99.8 atom-% D (deuterated) 
Cat. no. 151823 
Sigma-Aldrich (CH) 
Ethanol 
absolute, ≥ 99.8% 
Cat. no. 32205 
Sigma-Aldrich, Steinheim 
Ethyl acetate 
for analysis 
Cat. no. 10386320 
Fisher, Loughborough (UK) 
n-Hexane 
for analysis 
Cat. no. 24580.324 
VWR, Fontenay-sous-Bois (FR) 
Methanol 
HSL grade 
Cat. no. 670485 
CSC Jäklechemie, Nürnberg 
for analysis 
Cat. no. M/4000/17 
Fischer, Loughborough (UK) 
gradient grade for liquid chromatography 
(LiChrosolv®) 
Merck, Darmstadt 
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Cat. no. 1.06007.2500 
Petroleum ether 
isohexan 56/62, HSL grade 
Cat. no. 650065 
CSC Jäklechemie, Nürnberg 
RP-18 
LiChroprep® RP-18 (25-40 µm) for liquid 
chromatography 
Cat. no. 1.09303.0100 
Merck, Darmstadt 
CSi-gel 
Geduran® Si 60 for column 
chromatography (0.063-0.200 mm) 
Cat. no. 1.10832.9025 
Merck, Darmstadt 
Sulfuric acid 
95-97% GR for analysis 
Cat. no. 1.00731.1000 
Merck, Darmstadt 
Water 
0.055 – 0.062 µS/cm obtained upon 
occurrence from Astacus LS 
MembraPure, Bodenheim 
 
2.1.3 Plant material 
The flowering air parts of Hypericum triquetrifolium TURRA were collected on 23rd July, 2012 
along the Highway 91 between Ortal and Ein Zivan on Golan Heights, Israel. Approximate 
GPS coordinates are 33°05'22.8"N 35°47'18.7"E. 
The place where to find the plant was advised by Mrs. Michal Monosov, a curator of The 
Botanical Garden for Israeli Flora of the Hebrew University of Jerusalem on Mount Scopus. 
The plant material was identified and collected by the author of the present work and 
verified by Mrs. Hagar Leschner, collection manager of the National Israeli Herbarium of the 
Hebrew University (Berman building, Edmond J. Safra campus in Givat Ram, Jerusalem). The 
herb was dried under the RT (ca. 28 °C), stored at -80 °C for pest control and sent to 
Regensburg, Germany, via regular post. 
Voucher specimens number HUJ-131843, HUJ-131844 and HUJ-131845 were deposited at 
the National Israeli Herbarium of the Hebrew University of Jerusalem in Givat Ram. 
2.1.4 Extraction of plant material 
Air-dried aerial parts of Hypericum triquetrifolium TURRA (1023.5 g) were cut manually with 
scissors, then powdered and extracted by percolation with petroleum ether HSL grade (7.5 L) 
yielding 32.7 g crude extract (PE) after solvent evaporation. 
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2.1.5 Fractioning and isolation 
2.1.5.1 Flash Chromatography 
The raw PE extract was separated several times using Flash chromatography. Generally, first 
separation steps (fractions of larger quantities, more than 1000 mg) were conducted on Si-
gel, later steps (and smaller quantities, less than 1000 mg) – with RP-18 material. Fraction, 
which should have undergone the separation, was mixed with some quantity of stationary 
phase powder (ca. 2 – 3 times more than the weight of the fraction) and ca. 50-100 mL of 
solvent (hexane or MeOH). It was then rotated with a glass-frit-adapter on water bath 
evaporator under low-pressure to dry powder. The dried probe, mixed with the stationary 
phase, was placed into the pre-column. Two types of columns were used: pre- and main-
column, both manually packed (Tab. 5). 
Table 5. Manually packed columns for Flash chromatography 
№ Type 
Amount of 
stationary phase 
Packed 
volume 
Cartouche type 
Si-gel 
1 pre- ca. 25 g ca. 62 mL SVF D26, Götec (Germany) 
2 main- ca. 90 g ca. 228 mL SVP D40, Merck Chimie SAS (France) 
RP-18 material 
3 pre- ca. 4 g ca. 11 mL SVF D26, Götec (Germany) 
4 main- ca. 30 g ca. 74 mL  
 
Before the columns were installed, the device was purged with working solvents for 5-10 
min in order to remove air bubbles from the cables and the device. Then both pre- and main 
columns were installed into the Flash chromatograph and washed with 2-3 volumes of 
solvents (linear gradient, starting conditions). Afterwards the dry mixture of the fraction to 
be separated with stationary phase was placed in pre-column, and separation method 
started. When the running programme was over, columns were washed for ca. 15 min with 
100% MeOH or EtOAc (Si-gel and RP-18 respectively), Tab. 6. 
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Table 6. Methods and solvents for Flash chromatography 
Method Mobile phase Gradient, % Time, min 
Flow, 
mL/min 
Collection 
volume, mL 
Si-gel 
Flash_1 
Hexane-EtOAc 
0 → 100 EtOAc 
100 MeOH 
0-60 
60-75 
20 10 
Flash_2 10 10 
Flash_3 EtOAc-MeOH 
0 → 100 MeOH 
100 MeOH 
0-80 
80-110 
20 10 
RP-18 
Flash_4 
Water-MeOH 
70 MeOH 
70 → 90 MeOH 
90 MeOH 
90 → 100 MeOH 
100 MeOH 
100 EtOAc 
0-20 
20-25 
25-40 
40-45 
45-65 
65-80 
10 7.5 
Flash_5 
80 MeOH 
80 → 90 MeOH 
90 MeOH 
90 → 100 MeOH 
100 MeOH 
100 EtOAc 
0-15 
15-20 
20-35 
35-40 
40-60 
60-70 
15 7.5 
Flash_6 
H2O-MeOH 
 
35 MeOH 
35 → 40 MeOH 
40 → 60 MeOH 
60 → 75 MeOH 
75 MeOH 
100 EtOAc 
0-5 
5-10 
20-35 
35-40 
60-65 
65-75 
10 5 
 
Methods Flash_1 and Flash_3 occurred with two Si-gel columns (№ 1 and 2, Tab. 5), while 
method Flash_2 was performed with only one small SVF D26 type column, 2/3 filled with Si-
gel as stationary phase. Flash_4, Flash_5 and Flash_6 were conducted with both pre- and 
main columns (№ 3 and 4, Tab. 5). 
 
2.1.5.2 Fractions control 
2.1.5.2.1 Thin-layer chromatography (TLC) 
To control the obtained fractions and sub-fractions, etc. as well as to evaluate the results of 
separation (e.g. after CPC or Flash chromatography), TLC was performed. The main 
characteristic substance factor, describing this method is Rf, retardation factor. Rf is the ratio 
of the distance travelled by the centre of a spot to the distance travelled by the solvent 
front. The solvent system for the TLC analysis is considered ideal, when the investigated 
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compounds migrate on the plate between Rf values 0.3-0.8. Compounds distributed on the 
plate after the evaluation can be detected in daylight or in UV light, as well as detected with 
the use of various spray reagents. 
For this work Si-gel coated aluminium 20 x 20 cm plates were cut as appropriate. The sample 
(10 µl, concentration 1 mg/mL) was applied with a capillary (micro pipette) manually on the 
TLC plate and dried with common hair drier. Twin trough chamber was used to develop the 
plates. Chamber was filled with sufficient volume of the developing solvents mixture and 
well closed in order to bare the constant quantity of vapours inside. 
 mobile phase: hexane – EtOAc – acetic acid = 70:28:2 
Two sheets of filter paper were also placed inside to maintain the solvent’s vapours in all the 
volume of the chamber equable. A TLC plate with the applied probes was placed inside the 
filled chamber until the solvent reaches the front line. The plate was then dried in the 
laboratory hood with common drier and photographed (daylight, 254 and 366 nm). 
Derivatization was performed with AAR (subsequent heating 100 °C, ca. 5 min on a heat 
plate, until the spots are clearly developed on the plate) and immediately after that, pictures 
were taken (daylight and 366 nm). Specifications for TLC implements are described in Tab. 7. 
 AAR: anisaldehyde 0.5 mL, CH3COOH 10 mL, MeOH 85 mL, H2SO4 5 mL (Wagner et al., 
1983) 
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Table 7. TLC implements 
Instrument Specification Manufacturer 
Heat plate Thermoplate S Desaga, Nümbrecht 
Linomat 
Linomat 5 for sample application 
Syringe 100 µL 
Photo documentation: Reprostar 3 
Software: WinCats 1.4.2 
CAMAG, Muttenz (CH) 
Micro 
Pipettes 
Hirschmann® ringcaps® Duran® 250 pcs (10 µL) 
Cat. no. 9600110 
Hirschmann, 
Eberstadt 
BLAUBRAND® intraMARK 250 pcs (20 µL) 
Cat. no. 7087 18 
Brand, Wertheim 
TLC chamber Twin Trough chamber 20 x 20 cm Camag, Muttenz (CH) 
TLC devices 
Linomat 5 (Application); Reprostar 3 
(Documentation) 
WinCats 1.4.9.2001 (Software) 
Camag, Muttenz (CH) 
TLC plates 
Pre-coated aluminium TLC-sheets ALUGRAM® Xtra 
SIL G/UV254 silica gel 60, 20 x 20 cm 
Cat. no. 818333 
Macherey-Nagel, 
Düren 
Silica gel 60 RP-18 F254S aluminium sheets, 20x20 
cm 
Cat. no. 1.05554.0001 
Merck, Darmstadt 
 
For making overview TLC of high quality, an automatic sample applicator device (Linomat 5 
by CAMAG) was used. It sprays the liquid probe (20 µL) with nitrogen onto a TLC plate in a 
form of a band. Filling the syringe with probe solution, installing the syringe into the 
Linomat, taking it out and rinsing happened manually. All other operations were done 
automatically. A TLC plate with the applied probes was dried and placed into a TLC chamber 
as usual, following the common procedures, described above. 
Performing TLCs after Flash column chromatography or after CPC in order to evaluate the 
separation results and unite the obtained test-tubes in sub-fractions appropriately, probes 
were applied on the TLC plate directly from each test-tube. Concentration of the applied 
probe in this case could not be measured. 
2.1.5.2.2 1H-NMR spectroscopy 
In order to choose the correct fractions for further separation, 1H-NMR experiments were 
conducted with every fraction and sub-fraction obtained (NMR-guided fractionation). Each 
fraction or its part was solved in ca. 0.65 mL CDCl3, filled in a special NMR-test-tube with a 
cap and a proton spectrum was measured on Brucker Avance 300 at 300.13 MHz, 295 K. 
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Software TopSpin 3.2 was used to read the results, analyse and interpret the spectra. (§ 
2.1.6.1) 
2.1.5.3 Centrifugal Partition Chromatography 
This method refers to liquid-liquid chromatography techniques and is based on two 
immiscible liquid phases which are united together and form a two-phase system. CPC has 
being widely used for isolation and purification of natural products for almost 50 years 
(Friesen et al., 2015). This method let one get a very high selectivity, and also unlike 
traditional column chromatography, stationary phase is every time new, so it cannot be 
fouled and thus worsening the separation quality. 
In order to find an optimal solvent system for the separation, several known CPC conditions 
previously used for isolation of acylphloroglucinols from various Hypericum species were 
tested. The most suitable results were chosen for separation of PE-3 and PE-5 (Tab. 8) – this 
means, the fraction to be separated should be solved in both upper and lower phases 
equally and should be distributed identically in a parallel run on the same TLC plate (Fig. 19 
and Fig. 20). In both cases, during the main run in ascending mode the upper phase (organic, 
non-polar) was a mobile phase, while the lower phase (polar) served as a stationary one. 
 
Fig. 19. TLC test of the optimal solvent mixture for CPC for fraction PE-3 (Tab. 8). 
UP – PE-3 solved in upper phase, LOW – PE-3 solved in lower phase. 
Left: 254 nm, right: 366 nm. 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2 
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Fig. 20. TLC test of the optimal solvent mixture for CPC for fraction PE-5 (Tab. 8). 
UP – PE-5 solved in upper phase, LOW – PE-5 solved in lower phase. 
From left to right: 254 nm, 366 nm. 366 nm AAR, daylight AAR. 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2; derivatisation with AAR 
 
Table 8. Conditions for CPC separation 
Fraction 
Solvents 
mixture 
Flow 
Collection 
volume 
Rotation 
speed 
Previously used by 
PE-3 
hexane         8 
MeCN           5 
MeOH           2 
5 mL/min 
7.5 mL/test-
tube 
800 RPM 
Rocha et al., 1995 
PE-5 
hexane         83 
EtOH             67 
EtOAc           33 
H2O               17 
Decosterd et al., 
1989 
 
Prior to perform a CPC separation, solvent systems were prepared. All the solvents in 
designated proportions were united together in a separatory funnel. After intensive manual 
shaking the mixture was left alone for several seconds until the distinct border between two 
phases appeared. Both phases were separated, each one collected in a separate flask. 
The lower (stationary) phase was pumped into a rotor in sufficient quantity. It was followed 
by an upper (mobile) phase, at CPC rotation speed 800 rpm. The pumping of the upper 
phase continued until the equilibrium between both phases was reached. It was noted in a 
measuring cylinder, where the eluted lower phase was collected and its level remained 
steady. An extract fraction to be separated was well solved in a 50:50 mixture of upper and 
lower phases (1 g/4 mL of the mixture). The sample was injected in CPC manually with a 10 
40 | M a t e r i a l s  a n d  m e t h o d s  
mL Luer syringe, right after that the separation process began. The eluent was collected in 
glass test-tubes in the automatic fraction collector. 
With parallel TLC control, 300 test-tubes were collected in ascending mode. When no eluent 
spots were detected on a TLC plate, the CPC device was switched to the descending mode 
and 150 more test-tubes were collected. According to the TLC control, test tubes were 
united in sub-fractions, which were later purified with semi-preparative HPLC. 
2.1.5.4 Semi-preparative HPLC 
This was the last step in elucidating pure compounds. Fractions to be purified were solved in 
the solvents mixture equal to the starting conditions of the method, or in 100% MeCN. 
Solved fractions were filtrated through syringe filters with pore size 0.2 µm. Filtrated 
fractions were manually injected into an HPLC loop at room temperature. Concentration of 
the fractions injected was 10 mg/mL. Injection volume was ca. 250 µL each time (2.5 mg pro 
run). The separation was conducted on two columns (Tab. 9) with following conditions (Tab. 
10). 
Table 9. Columns for semi-preparative RP-HPLC 
№ Name Particles size Dimensions Manufacturer 
1 Eclipse XDB-C18 5 µm 9.4 x 250 mm Agilent Technologies (USA) 
2 
Vertex 
Eurosphere-100 C18 
7 µm 16 x 250 mm 
Dr. Ing. H. Knauer GmbH, 
Berlin 
 
Table 10. Separation solvents systems for semi-preparative HPLC 
Method Column Solvents Gradient, % Time, min Flow, mL/min 
HPLC_1 1 H2O-MeCN 80 → 100 MeCN 0-30 3 
HPLC_2 1 MeCN 100 MeCN 0-45 3 
HPLC_3 1 MeCN-MeOH 60 → 100 MeOH 0-30 2 
HPLC_4 1 MeCN-MeOH 70 → 100 MeOH 0-30 2 
HPLC_5 2 MeOH-MeCN 70 MeCN 0-30 5 
HPLC_6 2 H2O-MeCN 80 MeCN 0-50 10 
 
Collection of the fractions, i.e. corresponding peaks, seen on the monitor, occurred manually 
into the test-tubes. Results of several runs were united according to their retention time, 
wave length maximum and absorption similarities. The solvent from the united fractions was 
evaporated under constant nitrogen flow (overnight, laboratory hood, room temperature), 
then the fractions were weighted and NMR spectra were measured. 
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2.1.6 Structure elucidation and substances’ characterisation 
In order to characterise and describe the newly isolated substances, common spectroscopic 
and spectrometric methods were used, including: 
 NMR – Nuclear Magnetic Resonance 
 MS – Mass spectrometry 
 Polarimetry – optical rotation 
 UV-Spectra 
 CD – Circular dichroism 
Some of them (for example, 2D-NMR) are used to elucidate the structure of the newly 
isolated compound. Other methods, like MS may confirm the formula. CD-spectra help in 
determination of an absolute configuration, while other methods characterise the substance 
and may serve in future as a guiding landmark in discovering and characterising other similar 
compounds. 
2.1.6.1 NMR spectroscopy 
Fractions and sub-fractions underwent the 1H-NMR analysis in order to detect putative 
acylphloroglucinols whereas pure compounds were subjected to extensive NMR analyses to 
establish their structure. Each separate fraction or compound was solved in ca. 0.65 mL 
deuterated chloroform CDCl3 and placed in an NMR-tube so that the height of the solvent in 
the tube was not less than 4 cm. 
1D- and 2D experiments were measured at the Central Analytical department, Faculty of 
Chemistry and Pharmacy, University of Regensburg, Germany. Spectra were recorded at 298 
K, 600.25 MHz for 1H-NMR and 150.95 MHz for 13C-NMR. 
All the conducted NMR experiments may be divided in several groups: 
1) One dimensional: 
 1H-NMR 
 13C-NMR 
2) Two dimensional: 
a. Heteronuclear (1H, 13C): 
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 HSQC – Heteronuclear Single Quantum Coherence 
 HMBC – Heteronuclear Multiple Bond Correlation 
b. Homonuclear (1H, 1H): 
 COSY – Correlated spectroscopy 
 NOESY – Nuclear Overhauser Enhancement Spectroscopy 
In 1H-NMR spectrum various multiplets can be noted. They refer to the number of protons, 
according to the so called “n+1 rule”, where n is the number of neighbouring protons and 
multiplet refers to the investigated proton. In case of doublets (d), doublet of doublets (dd), 
triplets (t), sextets (sext.), septets (sept.), etc. a “coupling constant” (J, Hz) can be defined. 
After obtaining a 13C-NMR spectrum, a list of all the carbons may be printed out. With the 
help of HSQC experiment all the direct C-H bonds can be allocated. In this case one can 
observe blue and green cross-peaks (colours may depend on the software individual 
customizations). The first ones refer to either =CH– or –CH3 groups, while the latter shows –
CH2– groups. Quaternary carbons do not have any cross-peaks with any protons in this case, 
of course, because they cannot be connected with each other. HMBC shows then 
heteronuclear bonds between carbons and protons, which are maximum 4J far from each 
other. HMBC experiments were also particularly useful in determining quaternary carbons 
with very weak signals on 13C spectra or those, which didn’t show any visible signals at all. In 
this case HMBC allows seeing cross-peaks correlations between respective proton and 
quaternary carbon, thus enabling to confirm the bond. 
Homonuclear experiments, such as COSY show geminal (twins) (bonded to one and the same 
carbon, like in –CH2– group) or vicinal (neighbours) protons (each of them is bonded to the 
neighbouring carbon, like in –CH=CH–). NOESY helps to establish a relative stereochemistry 
configuration, based on correlations of protons, which are less than 5 Å far from each other 
in space. 
2.1.6.2 Mass spectrometry 
Mass experiments were conducted at the Mass spectrometry department of the Central 
Analytical division, Chemical-Pharmaceutical faculty, University of Regensburg, Germany. 
Moleculat weight and formula were obtained from high-resolution electrospray ionisation 
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spectra (ESI-HRMS), which were measured in positive or negative mode on Q-TOF 6540 UHD 
(Agilent). 
From the molecular ions M+ and quasi- or pseudo-molecular ions like, for example, [M + H]+ 
or [M - H]- and with the help of high-resolution precise determination of molecular weight 
and elemental composition analysis, an empirical formula of the investigated compound 
may be obtained (Budzikiewicz und Schäfer, 2012). 
2.1.6.3 Polarimetry 
Each one of the isolated substances was solved in MeOH HPLC grade (final concentration 
0.5 mg/mL, which equals 0.05 g/100 mL) and placed with a Pasteur pipette in a special 
cuvette (1 dm length) of the polarimeter. The measurements were conducted by room 
temperature with pure solvent as a reference solution. Wave length equals 589.0 nm, which 
corresponds with the D-line of sodium’s light. The specific rotation is calculated according to 
the formula 1 (Rücker et al., 2008): 
Formula 1. Calculation of optical rotation: 
    
  
     
   
 
where: 
 [α] – specific rotation 
 T – temperature in the moment of measurement, °C 
 D – D-line of sodium’s light, 589.0 nm 
 α – measured rotation, ° 
 c – concentration of the measured substance, 0.05 g/100 mL 
 l – pathlength of the cuvette, dm 
The polarimetry data, presented for each substance is an arithmetic mean value from six 
successional measurements with an interval of 4 seconds. 
2.1.6.4 UV-Visible spectroscopy 
Each one of the isolated substances were solved in MeOH HPLC grade (final concentration = 
0.6 mg/10mL) and placed in a special quartz cuvette for UV spectroscopy. This solution was 
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measured on UV spectrophotometer (λ = 200-800 nm, RT) with pure MeOH HPLC grade as a 
reference solution. 
The measurement gives the absorption maxima value. With its help the molar attenuation 
coefficient can be calculated, using a formula 2, resulting from Beer–Lambert law. 
Formula 2. Calculation of molar attenuation coefficient: 
   
 
   
 
where: 
 ε – molar attenuation coefficient, L · mol-1 · cm-1 
 A – absorption 
 c – molar concentration, mol/L 
 l – pathlength, 1 cm 
 
By describing the isolated substances, the data is presented by wave length value in nm, as 
well as by logarithmical form of the molar attenuation coefficient (log ε). 
 
2.1.6.5 CD spectroscopy 
For measurement of circular dichroism, a substance was solved in MeOH p.a. to give a 200 
µM solutiuon, filled in a quartz cuvette and measured on CD spectropolarimeter at room 
temperature with pure solvent as a reference. CD spectra graphs were constructed in 
Microsoft® Excel (relation of molar ellipticity from the wave length). Calculation of the molar 
ellipticity is possible, using the following equation (Rücker et al., 2008): 
Formula 3. Calculation of molar ellipticity: 
        
   
       
 
where: 
 [ ]M – molar ellipticity, ° · cm
2 · dmol-1 
   – ellipticity, ° 
 M – molar mass, g/mol 
 c – concentration, g/mL 
 l – pathlength, 0.1 dm 
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2.2 Cell culture methods 
The following chapter describes devices, expendables and software (§ 2.2.1), chemicals and 
reagents (§ 2.2.2), as well as culture mediums and other solutions (§ 2.2.3) used in cell 
culture experiments during the course of the present work. 
2.2.1 Devices, expendables and software 
Autoclave Autoklav 23, Melag, Berlin 
Varioklav 500, H+P, Oberschleißheim 
Centrifuge Megafuge 1.0 R Heraeus Sepatech, Heraeus Holding, Hanau 
Cell culture flask 75 cm2, 250 mL, PS, red filter cap, sterile 
Cat. no. 658-175, Greiner Bio-One GmbH, Frickenhausen 
Cryovials 2 mL, Greiner Bio-One, Frickenhausen 
Falcon centrifuge tubes 15 mL Cellstar® tubes (Cat. no. 188 271) 
50 mL Cellstar® tubes (Cat. no. 227 261), TPP, Trasadingen (CH) 
Filter, sterile Syringe filter PES 0.45 µm (Cat. no. 99745), TPP, Trasadingen 
(CH) 
Haemocytometer Neubauer improved, Brang, Wertheim 
Incubator NU-5500 E, NUAIRE, Plymouth (USA) 
Laminar flow cabinet HERASafeKS, Thermo, Langenselbold 
Microtiter plate Tissue culture Testplate 96F, Art. 92096, TPP, Trasadingen (CH) 
Microscopes 
(inverted light) 
CKX41SF, Olympus, Hamburg 
PrimoVert with camera and monitor, Zeiss, Göttingen 
Mixer Vortex Genius 3, IKA, Staufen 
Pasteur glass pipettes 230 mm (Cat. no. 612-1702), VWR, Darmstadt 
Heat-sterilized at 200°C during 3 h prior to use. 
Photometer (plate 
reader) 
SpectraFluor Plus, Tecan, Crailsheim; Xfluor4 v 4.40 (software) 
Pipette tips 200 µL, 1000 µL, Sarstedt, Nümbrecht; 10 µL, Axygen, Union 
City (USA). Pipette tips were autoclaved prior to use. 
Pipettes 2.5 Reference (0.1-2.5 µL), 10 Reference (2.5-10 µL) 
100 Research (10-100 µL), 1000 Research (100-100 µL) 
100 Research, 8-channel (10-100 µL), Eppendorf, Hamburg 
Pipettor Accu jet® pro, Brand, Wertheim 
Safe lock tubes Micro-centrifuge tubes for high g-force 1.5 mL natural, VWR, 
Radnor, PA (USA) (Cat. no. 211-0015) 
Safe lock tubes 2 mL, Eppendorf, Hamburg 
Serologic pipettes 5 mL (Cat. no. 606 180), 10 mL (Cat. no. 607 180) 
Greiner, Frickenhausen 
Syringe 1 mL Norm-Ject® Tuberkulin Luer (Cat. no. 4010-200V0) 
Henke Sass Wolf, Tuttlingen 
Ultrapure water supplier Astacus LS, MembraPure, Bodenheim 
Vacuum pump N 811 KT.18, KNF Neuberger, Freiburg 
Water bath WB22, Memmert, Schwabach 
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2.2.2 Chemicals and reagents 
Reagents Specifications and manufacturer 
DMEM Dulbecco’s Modified Eagle Medium, DMEM (1x) 
[+] 4.5 g/L D-Glucose, [+] L-Glutamine, [-] Pyruvate 
Cat. no. 41965-039 (500 mL), Cat. no. 41965-062 (10 x 500 mL) 
Gibco®, Life Technologies, Paisley (UK). Stored at 4 °C 
Used as DMEM + 10% FCS HI 
DMSO Dimethyl sulfoxide for molecular biology 100 mL, ≥ 99.5% 
Art. A994.1, Carl Roth GmbH, Karlsruhe 
FCS Fetal calf serum, Superior, LOT 1305 C; Biochrom, Berlin. Stored at -20 °C 
Used as FCS HI, heat-inactivated: water bath 56 °C, 30 min 
Glutamate Monosodium-L-glutamate, purity ≥ 99% (HPLC) 
Cat. no. 6445, Merk, Darmstadt 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
Thiazolyl Blue Tetrazolium Bromide 
Cat. no. M2128-5G, Sigma, St. Louis, MO (USA). Stored at 4 °C 
PBS Dulbecco’s Phosphate Buffered Saline (w/o CaCl2, MgCl2) 
Cat. no. D8537, Sigma life sciences, Steinheim. Stored at 4 °C 
Quercetin 3,3’,4’,5,7-pentahydroxyflavone, dehydrate 
Lot 14H0957, Sigma chemical Co., St. Louis, MO (USA) 
SDS Sodium dodecyl sulfate, 92.5 – 100.5% based on total alkyl sulfate content 
basis. Sigma-Aldrich, St. Louis, MO (USA). Cat. no. L5750-1KG 
Trypsin/EDTA 10x solution (0.5%/0.2%, w/v) in PBS, Cat. no. L 2153, Biochrom, Berlin 
Trypan blue 3-3‘-dimethyl-4,4‘-bis-(5-amino-4-hydroxy-2,7-disulfonaphtyl-3-azo)-[1,1‘-
biphenyl], dye content ca. 37%, Sigma-Aldrich, Taufkirchen 
 
2.2.3 Culture mediums and other solutions 
Medium Components Quantities 
Freezing medium for cryovials DMEM 70% 
FCS 20% 
DMSO 10% 
Growth medium DMEM 500 mL 
FCS HI 50 mL 
 
Solution Specifications Stored at 
Glu solution 1 M stock solution in PBS, sterile filtered -20 °C 
MTT solution 4 mg/mL MTT in PBS -20 °C 
SDS solution 10% (m/v) in millipore water RT 
Quercetin solution 50 mM stock solution in DMSO, sterile filtered -20 °C 
Trypan blue 0.4% (w/v) solution in PBS 4 °C 
Trypsin/EDTA 10% (v/v) solution in PBS 4 °C 
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2.2.4 Cells 
For the assays conducted in frames of this work, HT-22 cells were used (Fig. 21). This is a 
glutamate-sensitive immortalized mouse hippocampal sub-line, derived from parent HT4 
cells. Immortalization was performed with temperature sensitive SV40 T-antigen. (Davis and 
Maher, 1994; Maher and Davis, 1996; Morimoto and Koshland, 1990) 
Since HT-22 cells do not possess ionotropic NMDA receptors (Maher and Davis, 1996), Glu-
induced neurotoxicity occurs only via oxidative path. Therefore, Glu-induced, receptor 
mediated, excitotoxicity cell death pathway can be excluded (Kling, 2015) (§ 1.2.3, Fig. 18). 
In the course of the present work these cells were used for modelling and studying 
neurotoxicity and neuroprotection effects of the isolated acylphloroglucinol from H. 
triquetrifolium. 
The HT-22 cells were kindly supplied by the Max Plank Institute of Psychiatry, Munich 
(Germany). 
  
Fig. 21. Microscopic photograph of HT-22 cells (PX+8+3). Enlargement 10x (left), 20x (right). 
Photo edit: Dipl.-Ing. Igor Zeiger. 
 
2.2.5 Basic principles 
All the conducted experiments with HT-22 cells were performed under sterile conditions in a 
laminar flow cabinet following common cell culture procedures. (Schmitz, 2011) DMEM and 
PBS were warmed up to 37 °C on water bath prior to use. Trypsin and trypan blue solutions 
were left for 15-20 min to warm up at RT. 
48 | M a t e r i a l s  a n d  m e t h o d s  
DMEM is a growth medium suitable for HT-22 cells. It combines carbonate buffer, all the 
necessary nutritional chemicals for the cells, as well as pH indicator phenol red (pH of fresh 
DMEM is 7.1). When cells remain in the growth medium too long, their acidic waste 
products lower the pH value, which results in colour change of the medium. Red solution 
becomes orange and then yellow. Normally, this should not happen if cells are cultivated 
and splitted correctly. Furthermore, heat-inactivated FCS 50 mL was added to 500 mL 
growth medium DMEM bottle, making the final medium more rich in nutritional elements 
for cells, than the DMEM alone (§ 2.2.3). 
Thawing. HT-22 cells are kept in cryovials in a liquid nitrogen storage tank (temperature 
under atmospheric pressure is between ca. -210 °C and -196 °C). One cryovial contains 
1.8 mL freezing medium with about 1-2 million cells. The freezing medium for HT-22 cells 
consists of 70% DMEM + 20% FCS + 10% DMSO. FCS prevents crystallisation and restrains the 
clash. DMSO inhibits crystallisation as well, but in high concentrations it is very poisonous for 
the cells when they are defrosted. Therefore, after quick defrosting in a 37 °C water bath (in 
a beaker), cell suspension was diluted with 8 mL growth medium (1:5) and centrifuged at 
700 rpm (92 x g) for 4 min. Supernatant was removed and the remaining cells were 
suspended with 2 mL growth medium, which was then transferred to 18 mL fresh medium in 
a 75 cm2 culture flask. The flask was then placed in an incubator and fresh medium was 
exchanged in 2 days. 
Cultivation of HT-22 cells happened in incubator with the following conditions: temperature 
= 36.7 °C, CO2 level = 5%, humidity = 95%. Density and growth of the cells were observed 
under the microscope five times a week. 
Splitting of the cells occurred 3 times a week at around 80% confluence in order to keep the 
constant level of metabolic activity and their division efficiency. On Mondays and 
Wednesdays they were splitted in ratio 1:5 (for two days) and on Fridays 1:10 (for three 
days). For this purpose, growth medium from the culture flask was aspired with Pasteur 
pipette and the cells were washed with 10 mL PBS. Then 1 m of serine protease trypsin in 
EDTA was added. Since the cells are firmly hold on the internal surface of the culture flask 
with protein tails, which are stabilised with Ca2+ and Mg2+, EDTA complexes the ions and the 
enzyme functions better. (Boxberger, 2007) The culture flask was placed into incubator for 1 
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min until trypsin takes effect. Gentle clapping on the culture flask also helped to detach the 
cells. Then an excess of 9 mL of growth medium were added to the flask to dilute trypsin and 
stop its impact. The cells were well suspended and transferred into a falcon tube, then 
centrifuged at 700 rpm (92 x g) during 4 min. The supernatant was removed and cells were 
suspended in 5 mL fresh growth medium. In case of 1:5 splitting, 1 mL of this suspension was 
added to 19 mL growth medium in a new culture bottle. When the cells were splitted in ratio 
1:10, just 0.5 mL of the suspension was taken and dispensed in 19.5 mL growth medium. The 
cells in the flask were observed under the microscope and placed in incubator. Remaining in 
the falcon centrifuge tube cells were then used for further experiments (see below), or 
casted away if there was no need of immediate use. 
Estimating the cells quantity was performed using those 
ones, which were left in a falcon tube after the splitting (see 
above). Several drops of the suspension were taken to an 
Eppendorf 1.5 mL safe lock tube and 20 µL of this liquid was 
mixed in ratio 1:1 with 20 µL of diazo dye trypan blue solution 
(0.04 g in 10 mL PBS) (Fig. 23). An aliquot of this mixture (10 
µl) was placed under a glass lid into a Neubauer 
haemocytometer. Living cells do not let the trypan blue 
solution through their undamaged cell membranes and 
therefore remain uncoloured, whereas the dead cells take the dye. Only living cells were 
counted in 4 corner 4x4 squares (yellow coloured, see Fig. 22). An arithmetic mean was 
calculated, multiplied by two (because of the 1:1 dilution factor with trypan blue) and then 
multiplied by 104 (counting chamber conversion factor). The final value meant the quantity 
of cells in 1 mL suspension in the falcon tube. 
 
Fig. 23. Trypan blue (also known as diamine blue and Niagara blue) 
Fig. 22. Neubauer 
haemocytometer counting 
area 
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Substances. Previously isolated substances with elucidated structure were tested on HT-22 
cells. Having being kept in glass vials, sealed with Parafilm® “M” laboratory film, each 
substance was transferred to a safe lock tube, dried under the nitrogen flow and weighted. 
Weighting occurred six times, after which an arithmetical mean was estimated and used for 
further calculations. 
Stock solutions preparation. Dried and weighted substances were solved in DMSO 99.5% for 
molecular biology in order to obtain a 0.1 M stock solution. These were stored in safe lock 
tubes at -20 °C. 
2.2.6 MTT assay 
MTT assay is a useful and simple method to evaluate the quantity of living cells after 
toxicity/protection test. Since HT-22 cells do not possess ionotropic NMDA receptors, Glu-
induced neurotoxicity occurs in this case via oxytosis pathway (§ 1.2.3). Experiments were 
conducted in two stages: 
1) During the first stage, substances were tested on cells and their toxicity, i.e. 
neurotoxicity was observed. In this case they were compared to untreated cells in 
growth medium and pure solvent (0.05% DMSO) as control. 
2) On the second stage, tested substances were mixed with glutamate (5 mM Glu pro 
well) and should have protected the cells against ruinous activity of the latter. This 
time, the effects of the tested substances were compared to that of quercetin 
(positive control), since it is well known to protect neurons in low µM concentrations 
(Dok-Go et al., 2003). Glu acted as negative control and untreated cells in growth 
medium were considered as 100%. 
After a usual splitting, quantity of HT-22 cells in 1 mL growth medium was counted and 
calculated (§ 2.2.5). 96-well microtiter plates were used for the assay. Outer 36 wells were 
filled with only pure growth medium, whereas the internal 60 wells were used for the test. 
Cells were seeded in each one of these 60 internal wells in quantity of ca. 5000 cells in 100 
µL growth medium pro well. The microtiter plate with the cells was left in an incubator (t = 
36.7 °C, CO2 level = 5%, humidity = 95%) for 24 hours. 
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Investigated substance was solved in DMSO (max. 0.05%) to prepare a 0.1 M stock solution 
(kept in freezer), which was then diluted with growth medium to prepare a serial dilution 
with concentrations of 1, 5, 10 and 25 µM. The following controls were used to compare and 
analyse the data: 
 Untreated cells in growth medium (as 100%) 
 25 µM quercetin/DMSO + 5 mM Glu in growth medium as positive control 
 5 mM Glu/PBS in growth medium as negative control 
Impact of DMSO on the cells was studied separately (§ 3.2.1). 
After the cells were seeded and incubated for 24 hours, the supernatant was removed. 
100 µL of each 1-25 µM solution was subsequently placed in corresponding wells of the plate 
(6 wells for each solution), which was left in incubator for additional 24 hours after that. 
On the next day an MTT solution was prepared. Usually being stored in freezer, it has to be 
defrosted in water bath at 37 °C. Defrosted MTT solution (c = 4 mg/mL in PBS) was diluted 
with growth medium in ratio 1:10. 
Microtiter plate was taken out of the incubator and the applied substances were substituted 
with the MTT 1:10 diluted solution. The plate was once again placed in the incubator for 
3 hours, during which the yellow tetrazolium MTT salt was reduced to insoluble violet-blue 
formazan crystals (Fig. 24). 
 
Fig. 24. Reduction of MTT salt (yellow) to formazan (violet-blue) mainly occurs by cytosolic 
NADH- and NADPH-dependent oxidoreductases, as well as by mitochondrial reductases of 
metabolically active and viable cells. (Berridge et al., 1993; Berridge et al., 2005; Kling, 2015) 
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After 3 hours 10% water solution of sodium dodecylsulfat (SDS) (100 µL pro well) replaced 
the MTT one. It destroys cell membranes (and, as a result, the cells themselves) and solves 
formazan crystals. Microtiter plate was left for the night at RT in a dark place (because 
formazan can be photolabile) and on the next day the intensity of colouring was measured 
photometrically at 560 nm. 
Evaluation of results occurred in two ways, depending on the test: 
1) For neurotoxicity assay, untreated cells were used as 100% and an influence of the 
investigated substance on the HT-22 cells was expressed as percent to the number of 
untreated cells. Theoretically it might be expected, that the substances’ toxicity will 
rise with the increase of their concentration, although desirable is the constant high 
level of viable cells after the assay, which tends to 100% (untreated cells level). 
2) For neuroprotection assay, untreated cells were used as 100% as well, but also 
5 mM Glu and 25 µM quercetin (positive control) were used as controls. The tested 
substance in different concentrations was added to the cells along with Glu to 
observe its protecting properties in spite of a simultaneous impairment action of the 
amino acid. Data obtained on the impact of the tested compounds is compared to 
these three controls. Desirable are substances, which protect neuronal HT-22 cells on 
the same level as quercetin or better. 
Impact of the solvent. All the tested compounds were solved in DMSO in order to prepare 
0.1 M stock solutions, which were later diluted to the tested concentrations. In order to 
ensure the absence of any DMSO’s impact on the cells, three independent successive MTT-
assays (§ 2.2.6) with only pure cells and DMSO in concentrations 0.05%, 0.025% and 0.01% 
(in growth medium) were conducted (§ 3.2.1). 
2.2.7 Statistical analysis 
All experiments were conducted in hexaplicate and repeated three or more times 
independently from each other. The results are expressed as an arithmetic mean ± standard 
deviation, in % as a relation to 100% untreated cells. Statistical analysis was performed with 
Prism® 5.03 for Windows (GraphPad Software Inc., La Jolla, CA, USA) using one-way analysis 
of variances (ANOVA) to determine significant differences. Post hoc analysis was done using 
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the Dunnett’s test. Statistical significance levels: p < 0.05 (*), p < 0.01 (**) and p < 0.001 
(***). For significance test in neurotoxicity assays all results were compared to the untreated 
cells control, while in neuroprotection assays all results were compared to 5 mM Glu 
negative control. 
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3 Results and Discussion 
3.1 Phytochemical experiments 
3.1.1 Isolation strategy 
Talking about isolation strategies in general, three most common ones should be mentioned: 
 TLC-guided fractionation 
 NMR-guided fractionation 
 Bioactivity-guided fractionation 
Each one of them has its own advantages and disadvantages. For example, TLC-guided 
fractionation is a simple analytical method, which is cheap, easy and quickly to perform. On 
the other side, the spots can overlay on the plate, thus hiding and/or falsifying the results. 
Furthermore, the Rf values and spots’ colours are not specific constants to characterise a 
substance undoubtedly and unequivocally. 
NMR-guided fractionation may help in detecting compounds, while the ppm region is 
specific for certain functional groups. As an example and a guideline for all the isolated 
substances in the course of the present work, prenylated acylphloroglucinols may be 
detected according to several characteristic attributes (examples, Fig. 25): 
 
Fig. 25. Examples of structure elements with lacking or varying “down field shifted” 
hydrogen bonds in NMR-guided isolation strategy for acylphloroglucinols. 
 
 Specific “down field” singlets at δH > 13-15 ppm, usually 17-19 ppm. These do 
correlate with the hydrogen bond between the –OH group in the main phloroglucinol 
ring and =O of the starter acid (i) (also Fig. 63, § 3.1.3.1). In case of two –OH groups in 
ortho-position to a starter acid (ii), signal value will be “high field shifted” (ca. δH 11-
15 ppm), because the keto-group is able to build hydrogen bonds with them both. 
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However, absence of these signals doesn’t confirm the absence of 
acylphloroglucinols in the investigated probe (iii-v). 
 Characteristic are also triplets at ca. δH 5.00 ppm, which may indicate a =CH– group 
proton of the isoprene or geranyl rest (v). Exceptions from the rule are compounds, 
which are neither prenylated, nor geranylated or contain a cyclized side chain (i-iv). 
 Several compounds have been biosynthesized with isobutyryl CoA as a starter acid (i-
iii). In this case, a clear septet (ca. δH 2.50 – 3.50 ppm; δC 38-45 ppm), representing 
the aliphatic methine proton, as well as two doublets for each of the –CH3 groups (ca. 
δH 1.10 ppm) can be clearly observed. In representatives containing a 2-
methylbutyryl coA as starter acid (v), the methin proton will resonate as a sextet. A 
doublet (ca. δH 1.10 ppm) and a triplet (ca. δH 0.85 ppm) will be observed for the –
CH3 groups. In case of aromatic starter acid (iv), its protons’ signals will find place at 
around δH 7.00 ppm. 
 Signals of isoprene chains’ –CH3 groups (v) often show themselves as intensive high 
singlets at ca. δH 1.50 – 1.75 ppm, however these values may vary. 
 One can also obtain 13C-NMR spectra to confirm the presence of an 
acylphloroglucinol. In this case, there should be a different number of down field 
shifted signals (ca. δC 187-212 ppm), corresponding to the carbonyl carbons of the 
keto-groups (i-v). 
In addition to the exceptions described above, some other disadvantages lie in the fact that 
signals’ intensity of the crude extract spectrum do not always correlate with the quantity of 
the compounds in the probe. 
Unlike two previous strategies, bioactivity-guided fractionation always leads to an isolation 
of biologically active compounds. However, it is usually more expensive and takes more 
time, if compared to TLC- or NMR-guided methods. It is not also sensible to the fact that 
new, i.e. previously unknown compounds may possess different biological activity. It should 
be considered, that an extract or mixture of compounds may possess much higher biological 
activity, than that of one pure substance because of synergism. 
While performing the current work, NMR-guided strategy was used, thus resulting in 
isolation of 20 compounds, including acylphloroglucinols and their possible precursors. 
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Those isolated in sufficient quantities were tested for neurotoxicity and neuroprotection in 
vitro. 
3.1.2 Fractionation and isolation 
Obtained as described in § 2.1.4 a petroleum ether crude extract, PE (18.68 g) from H. 
triquetrifolium TURRA (1H-NMR, Fig. 26), was divided in four equal parts in order to undergo 
the first separation step on Si-gel Flash column chromatography. This was done because of 
the limited columns’ capacity. Mobile phase was used as described in method Flash_1 (§ 
2.1.5.1). 
 
Fig. 26. 1H-NMR of crude PE extract (300.13 MHz, 295 K) 
The separation resulted in 6 fractions. Four identical subsequent runs were checked by TLC- 
and NMR-fractions control. These allowed uniting equal corresponding fractions from each 
of the four runs together. Principal separation scheme of PE extract is presented in Fig. 27. 
 
Fig. 27. Separation scheme for crude PE extract. 
 
57 | R e s u l t s  a n d  D i s c u s s i o n  
Weights and volumes of sub-fractions, obtained after Flash fractionation of PE extract of H. 
triquetrifolium. 
Flash 1: PE-1 0.59 g, 100 mL; PE-2 0.74 g, 140 mL; PE-3 0.54 g, 210 mL; PE-4 0.34 g, 190 mL; 
PE-5 0.28 g, 430 mL; PE-6 0.31 g, 70 mL 
Flash 2: PE-1 3.69 g, 300 mL; PE-2 1.03 g, 110 mL; PE-3 1.36 g, 300 mL; PE-4 0.25 g, 160 mL; 
PE-5 0.17 g, 190 mL; PE-6 0.08 g, 180 mL 
Flash 3: PE-1 5.31 g, 380 mL; PE-2 0.88 g, 100 mL; PE-3 2.35 g, 280 mL; PE-4 0.29 g, 190 mL; 
PE-5 0.14 g, 190 mL; PE-6 0.56 g, 250 mL 
Flash 4: PE-1 3.25 g, 380 mL; PE-2 1.07 g, 100 mL; PE-3 1.80 g, 280 mL; PE-4 0.28 g, 190 mL; 
PE-5 0.13 g, 190 mL; PE-6 0.57 g, 300 mL 
 
3.1.2.1 Fractionation of PE-2 
Separation scheme of PE-2 can be observed from Fig. 28. 
 
Fig. 28. Separation scheme of PE-2. 
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PE-2 (3.44 g) was separated with Flash chromatography on Si-gel (method Flash_1), giving 6 
fractions (PE-2.1 844.5 mg, 190 mL; PE-2.2 102.3 mg, 130 mL; PE-2.3 1591.6 mg, 250 mL; PE-
2.4 459.0 mg, 190 mL; PE-2.5 218.9 mg, 440 mL; PE-2.Rest 237.2 mg, 300 mL) in 150 test-
tubes (10 mL/each). The overview TLC on Si-gel for these fractions is presented on Fig. 29. 
 
Fig. 29. TLC of PE-2.1–2.Rest (366 nm) 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2 
 
Fractions PE-2.2, PE-2.3 and PE-2.5 show dark, almost black-blue bands at Rf 0.16, 0.19 and 
0.30 respectively. They are characteristic for phenolic compounds and may point on the 
presence of some acylphloroglucinols in the probe (Schmidt, 2013). 
PE-2.1 (844.5 mg, 190 mL eluted) was separated with Flash column chromatography on Si-
gel (method Flash_2), giving 6 sub-fractions (PE-2.1.1 164.8 mg, 120 mL; PE-2.1.2 390.6 mg, 
80 mL; PE-2.1.3 35.9 mg, 50 mL; PE-2.1.4 18.0 mg, 60 mL; PE-2.1.5 9.4 mg, 70 mL; PE-
2.1.Rest 31.0 mg, 320 mL) in 70 test tubes (10 mL/each), out of which PE-2.1.1 (164.8 mg, 
120 mL eluted) was subsequently separated on RP-18 Flash column chromatography 
(method Flash_4), giving 6 sub-fractions (PE-2.1.1.1 5.2 mg, 285 mL; PE-2.1.1.2 4.9 mg, 75 
mL; PE-2.1.1.3 21.5 mg, 75 mL; PE-2.1.1.4 36.0 mg, 135 mL; PE-2.1.1.5 5.3 mg, 158 mL; PE-
2.1.1.Rest 67.9 mg, 75 mL) in 107 test tubes (7.5 mL/each). According to its 1H-NMR 
spectrum (Fig. 30), fraction PE-2.1.1.4 looked very promising regarding a search for 
acylphloroglucinols: characteristic “down field” signals at δH 19.00 ppm and 10.00 ppm 
suggesting an intramolecular hydrogen bond, a septet resonating at 2.95 ppm represents the 
aliphatic methine proton of the isobutyric starter acid, as well as 2 doublets at 0.99 and 1.02 
ppm may depict both –CH3 groups. Additional singlets at 1.15 and 1.70 ppm may stand for 
isoprene rests’ –CH3 groups. PE-2.1.1.4 (36.0 mg, 135 mL eluted) was purified on semi-
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preparative HPLC (method HPLC_5) giving (+)-yezo’otogirin C (11) (tR 15.8 min; λmax 211, 302 
nm; Fig. 30). 
 
 
Fig. 30. PE-2.1.1.4 1H-NMR (300.13 MHz, 295 K)  (left) 
HPLC chromatogram at 211 nm, HPLC_5 (right) 
 
PE-2.2 (102.3 mg, 130 mL eluted) was separated by Flash chromatography on RP-18 (method 
Flash_4), giving 11 sub-fractions (PE-2.2.1 18.3 mg, 158 mL; PE-2.2.2 14.6 mg, 53 mL; PE-
2.2.3 13.6 mg, 120 mL; PE-2.2.4 17.3 mg, 45 mL; PE-2.2.5 63.0 mg, 30 mL; PE-2.2.6 41.3 mg, 
90 mL; PE-2.2.7 32.7 mg, 38 mL; PE-2.2.8 7.0 mg, 23 mL; PE-2.2.9 12.5 mg, 53 mL; PE-2.2.10 
7.1 mg, 105 mL; PE-2.2.Rest 43.6 mg, 90 mL) from 107 test tubes (7.5 mL each). Because of 
its clear “down field” signals on 1H-NMR spectrum, fraction PE-2.2.9 (12.5 mg, 53 mL eluted) 
was chosen for further HPLC purification (method HPLC_4), resulting in triquetriborin (1) (tR 
22.0 min; λmax 205, 243, 287 nm; Fig. 31). 
 
 
Fig. 31. PE-2.2.9 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 289 nm, HPLC_4 (right) 
 
PE-2.3 (1591.6 mg, 250 mL eluted) was separated with Flash column chromatography on Si-
gel (method Flash_2), giving 5 sub-fractions (PE-2.3.1 40.3 mg, 110 mL; PE-2.3.2 665.6 mg, 
110 mL; PE-2.3.3 232.7 mg, 90 mL; PE-2.3.4 79.9 mg, 190 mL; PE-2.3.Rest 63.2 mg, 200 mL) 
in 70 test tubes (7.5 mL each). The fraction with the highest quantity, PE-2.3.2 (665.6 mg, 
60 | R e s u l t s  a n d  D i s c u s s i o n  
110 mL eluted) (Fig. 32) was once again separated with Si-gel Flash chromatography 
(method Flash_2), resulting in 70 test tubes (7.5 mL each), which were combined to 7 sub-
fractions (PE-2.3.2.1 7.0 mg, 100 mL; PE-2.3.2.2a 20.1 mg, 20 mL; PE-2.3.2.2b 58.2 mg, 20 
mL; PE-2.3.2.3 299.1 mg, 80 mL; PE-2.3.2.4 35.1 mg, 90 mL; PE-2.3.2.5 18.4 mg, 140 mL; PE-
2.3.2.Rest 28.4 mg, 250 mL). 
 
Fig. 32. 1H-NMR of PE-2.3.2 (300.13 MHz, 295 K) 
 
PE-2.3.2.2a (20.1 mg, 20 mL eluted) was purified on semi-preparative HPLC (method 
HPLC_3) giving a mixture of triquetriirinon A and B (12+13) (tR 9.9 min; λmax 207, 294 nm) and 
(+)-yezo’otogirin C (11) (tR 16.0 min; λmax 210 nm) (Fig. 33). 
  
Fig. 33. PE-2.3.2.2a 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 209 nm, HPLC_3 (right) 
 
PE-2.3.2.2b (58.2 mg, 20 mL eluted) was purified on semi-preparative HPLC (method 
HPLC_3) giving a mixture of triquetriirinon A and B (12+13) (tR 9.8 min; λmax 207 nm; Fig. 34). 
Right as in the case of sub-fraction PE-2.3.2.2a these both compounds couldn’t be separated 
and eluted together. 
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Fig. 34. PE-2.3.2.2b 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 210 nm, HPLC_3 (right) 
 
PE-2.3.2.Rest (28.4 mg, 250 mL eluted) was purified by semi-preparative HPLC (method 
HPLC_2, time = 15 min) giving pure triquetriirinon A (12) (tR 9.0 min; λmax 203, 216, 280 nm; 
Fig. 35). 
 
 
Fig. 35. PE-2.3.2.Rest 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 202 nm, HPLC_2 (right) 
 
PE-2.Rest (237.2 mg, 300 mL eluted) (Fig. 36) was separated with Flash on RP-18 (method 
Flash_4), giving 7 fractions (PE-2.Rest.1 45.3 mg, 210 mL; PE-2.Rest.2 6.2 mg, 90 mL; PE-
2.Rest.3 14.4 mg, 53 mL; PE-2.Rest.4 5.5 mg, 30 mL; PE-2.Rest.5 75.7 mg, 120 mL; PE-
2.Rest.6 27.7 mg, 210 mL; PE-2.Rest.Rest 21.3 mg, 90 mL) in 107 test-tubes (7.5 mL each). 
Fraction PE-2.Rest.5 (75.7 mg, 120 mL eluted) was subsequently purified on semi-
preparative HPLC (method HPLC_3) yielding triquetriirinon A (12) (tR 10.3 min; λmax 213, 282 
nm) and triquetriirinon C (14) (tR 11.3 min; λmax 205, 248, 323 nm) (Fig. 37). 
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Fig. 36. TLC of PE-2.Rest 
From left to right: 254 nm, 366 nm, 366 nm AAR, daylight AAR. 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2 
 
 
 
Fig. 37. PE-2.Rest.5 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 211 nm, HPLC_3 (right) 
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3.1.2.2 Fractionation of PE-3 
Separation scheme of PE-3 can be observed from Fig. 38. 
 
Fig. 38. Separation scheme of PE-3. 
  
Fig. 39. TLC on Si-gel of PE-3 
(from left to right: 254 nm, 366 nm, 
366 nm AAR, daylight AAR) 
hexane – EtOAc – acetic acid = 70:28:2 
Fig. 40. 1H-NMR of PE-3 (300.13 MHz, 295 K) 
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Fraction PE-3 looked very promising in search for acylphloroglucinols according to its TLC 
(Fig. 39) and 1H-NMR spectrum (Fig. 40). Characteristic “down field shifted” signals, as well 
as blue bands at Rf ca. 0.31 and 0.53 (366 nm) point on the presence of desirable chemicals 
in the probe. 
PE-3 (8.30 g) was separated using CPC (Tab. 8, § 2.1.5.3). Because the loading quantity into a 
CPC device is limited, the separation occurred in four runs, namely “0”, “1”, “2” and “3”. TLC- 
and NMR- control of the sub-fractions revealed identical results for runs 0-3. However 
similar corresponding sub-fractions were not united. Their subsequent fractionating 
occurred separately. 
After each CPC separation run, 8 sub-fractions were obtained. According to their 1H-NMR 
spectra and overview TLCs four fractions were chosen for later separation: from run 1 – PE-
3.4(1) and from run 2 – PE-3.2(2), PE-3.5(2) and PE-3.Rest(2). TLCs of the sub-fractions 
obtained after CPC on the example of run 2 are presented in Fig. 41. 
  
  
Fig. 41. TLC. Example of sub-fractions of PE-3 after separation on CPC, shown is run 2. 
Up left: 254 nm; up right: 366 nm; down left: daylight AAR; down right: 366 nm AAR 
Bands from left to right: PE-3.1 – 3.5, 3.5a, 3.Rest and “lower phase wash” sub-fraction 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2 
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Weight and volume of sub-fractions, obtained during the run “1” CPC of PE-3: PE-3.1(1) 
461.3 mg, 330 mL; PE-3.2(1) 75.2 mg, 180 mL; PE-3.3(1) 46.4 mg, 135 mL; PE-3.4(1) 156.8 
mg, 480 mL; PE-3.5(1) 104.6 mg, 255 mL; PE-3.Rest(1) 151.2 mg, 1433 mL; PE-3.LP(1) 72.54 
mg, 788 mL. Fraction PE-3.LP(1) was obtained during the wash of the CPC with the 
descending mode. 
Weight and volume of sub-fractions, obtained during the run “2” CPC of PE-3: PE-3.1(2) 
655.3 mg, 293 mL; PE-3.2(2) 92.3 mg, 158 mL; PE-3.3(2) 73.0 mg, 255 mL; PE-3.4(2) 127.7 
mg, 360 mL; PE-3.5(2) 61.7 mg, 180 mL; PE-3.5a(2)-110.6 mg, 255 mL; PE-3.Rest(2) 155.4 mg, 
1313 mL; PE-3.LP(2) 121.9 mg, 795 mL. Fraction PE-3.LP(2) was obtained during the wash of 
the CPC with the descending mode. 
PE-3.4(1) (156.8 mg, 480 mL eluted) underwent a Flash column chromatography separation 
on RP-18 (method Flash_5), giving seven fractions in 140 test tubes (7.5 mL/each). 
Weight and volume of sub-fractions, obtained during the Flash separation of PE-3.4(1): PE-
3.4(1)0 12.6 mg, 98 mL; PE-3.4(1)1 24.9 mg, 53 mL; PE-3.4(1)2 32.2 mg, 135 mL; PE-3.4(1)3 
19.8 mg, 120 mL; PE-3.4(1)4 6.9 mg, 75 mL; PE-3.4(1)5 16.5 mg, 420 mL; PE-3.4(1)Rest 6.4 
mg, 150 mL. It was decided to purify fractions PE-3.4(1)-2 and PE-3.4(1)-3 on semi-
preparative HPLC. 
PE-3.4(1)-2 (32.2 mg, 135 mL eluted) was separated using method HPLC_1, but according to 
1H-NMR spectra all three obtained sub-fractions were not pure enough to conduct 2D-NMR 
experiments (Fig. 42): PE-3.4(1)2.1 (tR 10.8 min), PE-3.4(1)2.2 (tR 11.2 min) and the rest was 
collected in PE-3.4(1)2.Rest. It was then decided to additionally purify these sub-fractions 
with another HPLC method. 
 
Fig. 42. 1H-NMR of PE-3.4(1)-2 (300.13 MHz, 295 K) 
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PE-3.4(1)-2.2 (3.2 mg; tR 11.2 min) was purified on semi-preparative HPLC (method HPLC_2) 
giving triquetriroxettin (9) (tR 7.7 min; λmax 202, 274 nm; Fig. 43). 
  
Fig. 43. PE-3.4(1)-2.2 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 274 nm, HPLC_2 (right) 
 
PE-3.4(1)-2.Rest (19.9 mg) was purified on semi-preparative HPLC (method HPLC_2) giving 
triquetrireboudin B (6) (tR 9.6 min; λmax 207 nm) and triquetriroxettin (9) (tR 8.4 min; λmax 
202, 274 nm) (Fig. 44). 
  
Fig. 44. PE-3.4(1)-2.Rest 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 276 nm, HPLC_2 (right) 
 
PE-3.4(1)-3 (19.8 mg, 120 mL eluted) was purified on semi-preparative HPLC (method 
HPLC_1) giving triquetribavarin (10) (tR 10.2 min; λmax 203, 279 nm; Fig. 45). 
  
Fig. 45. PE-3.4(1)-3 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 203 nm, HPLC_1 (right) 
67 | R e s u l t s  a n d  D i s c u s s i o n  
PE-3.2(2) (92.3 mg, 158 mL eluted) was purified on semi-preparative HPLC (method HPLC_1) 
giving linoleic acid (17) (tR 16.3 min; λmax 206 nm; Fig. 46). 
 
 
Fig. 46. PE-3.2(2) 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 203 nm, HPLC_1 (right) 
 
PE-3.5(2) (61.7 mg, 180 mL eluted) was purified on semi-preparative HPLC (method HPLC_1) 
giving triquetrireboudin A (4) (tR 8.2 min; λmax 210, 276 nm; Fig. 47). 
 
 
Fig. 47. PE-3.5(2) 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 277 nm, HPLC_1 (right) 
 
PE-3.Rest(2) (155.4 mg, 1313 mL eluted) was purified on semi-preparative HPLC (method 
HPLC_1) giving triquetrikotelin A (7) (tR 9.6 min; λmax 215, 268 nm), triquetrikotelin B (8) (tR 
10.8 min; λmax 203, 268 nm) and triquetrireboudin Aa (5) (tR 15.6 min; λmax 216, 276 nm) (Fig. 
48). 
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Fig. 48. PE-3.Rest(2) 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 275 nm, HPLC_1 (right) 
 
 
3.1.2.3 Fractionation of PE-4 
Separation scheme of PE-4 can be observed from Fig. 49. 
 
Fig. 49. Separation scheme of PE-4. 
PE-4 (1.48 g) was first separated with Si-gel Flash chromatography (method Flash_2). The 
process resulted in 4 fractions (PE-4.1 21.2 mg, 150 mL; PE-4.2 519.6 mg, 230 mL; PE-4.3 
212.7 mg, 220 mL; PE-4.Rest 142.0 mg, 100 mL) in 70 test tubes (10 mL/each). 
PE-4.1 (21.2 mg, 150 mL eluted) was purified on semi-preparative HPLC (method HPLC_3) 
giving triquetriirinon A (12) (tR 10.8 min; λmax 204, 284 nm; Fig. 50). 
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Fig. 50. PE-4.1 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 204 nm, HPLC_3 (right) 
 
PE-4.2 (519.6 mg, 230 mL eluted) was separated using Flash column chromatography on Si-
gel (method Flash_2). Obtained are 5 sub-fractions (PE-4.2.1 152.2 mg, 130 mL; PE-4.2.2 39.3 
mg, 110 mL; PE-4.2.3 237.4 mg, 260 mL; PE-4.2.4 8.3 mg, 100 mL; PE-4.2.Rest 44.6 mg, 100 
mL) in 70 test-tubes (10 mL/each). 
PE-4.2.2 (39.3 mg, 110 mL eluted) was purified on semi-preparative HPLC (method HPLC_3) 
giving linoleic acid (17) (tR 12.6 min; λmax 203, 211, 273 nm; Fig. 51). 
  
Fig. 51. PE-4.2.2 (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 203 nm, HPLC_3 (right) 
 
PE-4.2.3 (237.4 mg, 260 mL eluted) was purified on semi-preparative HPLC (method HPLC_3) 
giving α-linolenic acid (16) (tR 10.6 min; λmax 204, 273 nm; Fig. 52). 
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Fig. 52. PE-4.2.3 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 202 nm, HPLC_3 (right) 
 
PE-4.3 (212.7 mg, 220 mL eluted) was chosen because of the characteristic “down field 
shifted” signal at ca. δH 18.30 ppm (Fig. 53), which could have denoted the presence of an 
acylphloroglucinol. The fraction was purified on semi-preparative HPLC (method HPLC_1, 
time = 50 min) giving triquetrijakobin A (2) (tR 29.8 min; λmax 203, 244, 322 nm) and 
triquetrijakobin B (3) (tR 30.7 min; λmax 203, 245, 322 nm) (Fig. 53). 
 
 
Fig. 53. PE-4.3 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 203 nm, HPLC_1 (right) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 | R e s u l t s  a n d  D i s c u s s i o n  
3.1.2.4 Fractionation of PE-5 
Separation scheme of PE-5 can be observed from Fig. 54. 
 
Fig. 54. Separation scheme of PE-5. 
Fraction PE-5 was selected for further separation according to characteristic blue bands at Rf 
ca. 0.27 (366 nm) on a Si-gel TLC plate (Fig. 55), as well as because of the clear signals in 
“down field” on its 1H-NMR spectrum, meaning the possible presence of acylphloroglucinols 
(Fig. 56). 
 
 
Fig. 55. TLC on Si-gel of PE-5. 
From left to right: 254 nm, 366 nm, 
366 nm AAR, daylight AAR. 
hexane – EtOAc – acetic acid = 70:28:2 
Fig. 56. 1H-NMR of PE-5 (300.13 MHz, 295 K) 
 
PE-5 (0.63 g) was separated with CPC. Several systems previously used in various Hypericum 
species were tested, just as for the fraction PE-3. The most suitable solvent mixture 
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appeared to be hexane : EtOH : EtOAc : H2O = 83 : 67 : 33 : 17 (Decosterd et al., 1989). With 
the conditions described in Tab. 8, § 2.1.5.3, nine sub-fractions were obtained (Fig. 57). 
  
  
Fig. 57. TLC, PE-5 sub-fractions after CPC separation. 
Left up: 254 nm; right up: 366 nm; left down: daylight AAR; right down: 366 nm AAR 
Bands from left to right: PE-5.1 – 5.7, 5.Rest and “lower phase wash” sub-fraction. 
Si-gel; hexane – EtOAc – acetic acid = 70:28:2 
 
After CPC run of PE-5 eight fractions (PE-5.1 3.8 mg, 75 mL; PE-5.2 210.9 mg, 83 mL; PE-5.3 
69.0 mg, 68 mL; PE-5.4 84.9 mg, 195 mL; PE-5.5 32.3 mg, 135 mL; PE-5.6 48.4 mg, 323 mL; 
PE-5.7 30.5 mg, 405 mL; PE-5.Rest 27.0 mg, 975 mL) in 300 test-tubes (7.5 mL/each) were 
obtained. 
Each obtained sub-fraction underwent 1H-NMR measurement for fractions control. From 
which, sub-fraction PE-5.3 looked promising in quest of acylphloroglucinols because of 
characteristic down-field signal and signals for probable isoprene-chain proton at ca. δH 5.00 
ppm (Fig. 58). 
PE-5.3 (69.0 mg, 68 mL eluted) underwent the last purification step with semi-preparative 
HPLC (method HPLC_1). Triquetriirinon D (15) was isolated (tR 15.9 min; λmax 202, 274 nm; 
Fig. 58). 
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Fig. 58. PE-5.3 1H-NMR (300.13 MHz, 295 K) (left) 
HPLC chromatogram at 202 nm, HPLC_1 (right) 
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3.1.2.5 Fractionating of methanolic extract 
The study of methanolic extract (ME) obtained from H. triquetrifolium was conducted in 
frames of a PhD-student-guided internship practice of Mr. Marcell Kaljanac on 
Pharmaceutical Biology department (University of Regensburg) (internship mentor: Ilya B. 
Volkov). The aim of this part of work was to elucidate some flavonoids and thus characterise 
the herb not only with its nonpolar constituents. 
The fractionation of ME occurred with the same NMR-guided strategy. In this case, 
important landmarks on 1H-NMR spectra were: 
 Signals at ca. δH 7.00 ppm, usual for protons in aromatic rings 
 Signals at δH 3.00 – 4.00 ppm, usual for sugars (in case of glycosides) 
Obtained as described in § 2.1.4 ME extract (189.47 g) was used for partial research. 6.6 g of 
crude ME extract was separated on Si-gel Flash column chromatography, giving 5 fractions 
(Fig. 59). ME-3 (897.5 mg) was separated with RP-18 Flash chromatography, resulting in 11 
sub-fractions. ME-3.3 (265.7 mg) was finally purified on preparative HPLC (RP-18) (method 
HPLC_6), yielding in 18 and 19+20. 
 
Fig. 59. Separation scheme of crude methanolic extract (ME). 
ME-4 (2615.0 mg) was separated on RP-18 Flash chromatography, giving 7 sub-fractions. 
ME-4.3 (117.0 mg) was finally purified on preparative RP-18 HPLC (method HPLC_6), 
resulting in 18. 
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3.1.3 Structure elucidation and characterisation of isolated compounds 
Structure elucidation was conducted using 1D- and 2D-NMR experiments (1H, 13C, HSQC, 
HMBC, COSY and NOESY). MS experiments confirmed the structure. In order to characterise 
the substances, specific rotation, UV- and CD-spectra were also measured, recorded and 
calculated. 
3.1.3.1 General principles in structure elucidation 
There is of course a vast variety of different approaches on how to determine a molecule 
structure according to its 2D-NMR spectra. The following approximate algorithm was used 
during the course of the present work (see also § 2.1.6.1): 
The List. The list of all 13C signals (i.e. the list of all the carbons belonging to the compound) 
was printed out and each carbon was correlated to the respective hydrogen according to the 
HSQC experiment, thus making direct bonds clear, as well as marking whether the carbon is 
quaternary or refers to a –CH3, –CH2– or =CH– group. Multiplicity of hydrogens was also 
noted using a 1H-NMR signal list. 
Isoprene chain. Typical triplets in 1H-NMR spectrum at ca. δH 5.00 
ppm were chosen to indicate a prenyl side chain. They should 
represent a proton of an isoprene based side chain (=CH– group) 
as the value is shifted towards the “down field”. HMBC and COSY 
helped in determination of the atoms consequence in the chain. –
CH2– groups’ protons show HMBC correlations with a carbon at ca. 
δC 38-42 ppm, which is usually referred to the main core of the 
molecule (Fig. 60). 
Starter acid. Keto group – quaternary carbon, connected to an oxygen with a double bond, 
usually resonates in acylphloroglucinols at ca. δC 197-218 ppm in a 
13C spectrum (Fig. 61, a). 
In HMBC it is clearly “seen” by a proton of the methine carbon, which multiplicity is either 
usually a septet (isobutyryl) (Fig. 62) or less often a pseudo-sextet (2-methylbutyryl). In case 
of isobutyryl both –CH3 groups are characterised by two doublets at ca. δH 1.10 ppm each, 
while in 2-methylbutyryl starter acid there’s an additional –CH2– group and thus the terminal 
–CH3 group resonated as a triplet at ca. δH 0.85 ppm (Fig. 61, b). 
Fig. 60. Isoprene rest 
on a six membered 
ring (2D NMR 
correlations). 
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Fig. 61. Starter acid’s approximate δC (a) and δH (b) 
values, ppm. Differences can be noted between 
isobutyryl (left) and 2-methylbutyryl (right). 
Fig. 62. Example of a characteristic 
septet at δH 2.96, indicating an 
aliphatic methine proton in an 
isobutyryl side chain. (300.13 MHz, 
295 K). 
 
Intramolecular hydrogen bonds. Many acylphloroglucinols (not all though, § 3.1.1) build 
characteristic intramolecular hydrogen bonds, which can be clearly seen seen in a 1H-NMR 
spectra as “down field shifted” signals at ca. δH 14-19 ppm. This happens between –OH 
group of the main phloroglucinol skeleton and oxygen from the starter acid’s keto group 
(Fig. 63). 
 
 
Fig. 63. Intramolecular 
hydrogen bond 
Fig. 64. Undetectable hydroxyl group 
(in position 4) 
 
Undetectable hydroxyl groups. During the elucidation process some uncertainties in pyran 
ring occurred. In HSQC C-4 (Fig. 64) was identified as a methine carbon. Both the carbon and 
the proton directly connected to it possess unusually high chemical shift values: ca. δC 94 
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ppm, δH 4.65 ppm. This let suggesting the presence of an ether group directly coupled to the 
carbon in position 4. However, HMBC showed only correlations between the atoms in 
position 4 and those in positions 1, 3, 5, 6, 11 and 12. No further correlations (i.e. those, 
lying beyond the proposed oxygen out of the pyran ring) in an HMBC experiment were noted 
in order to prolong the chain further. This in turn let hypothesizing the presence of a 
hydroxyl group, connected to C-4. High resolution MS experiments (HRESIMS) when the 
molecular formula was calculated, later confirmed the presence of an –OH group in this 
position, which was indeed not visible in any 1D- or 2D-NMR experiment most probably due 
to deuterium exchange with the solvent. 
Molecule’s main core was elucidated using usual correlations in HMBC and COSY 
experiments. Relative stereochemistry was defined via NOESY. 
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3.1.3.2 Prenylated acylphloroglucinols 
Compound 1 (Triquetriborin) 
Tab. 11. 1H and 13C data in CDCl3 (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
C/H δC δH mult (J in Hz) 
1 56.1  
2 199.6  
3 144.8  
4 194.3  
5 69.9  
6 50.7  
7 39.4 1.76 (1H, m) 
8 40.4 
1.95 (1H, m) 
2.24 (1H, d, 14.5) 
9 208.5  
10 17.5 1.32 (3H, s) 
11 18.7 1.24 (3H, s) 
1‘ 207.4  
2‘ 35.0 3.85 (1H, sept) 
3‘ 18.5 1.20 (3H, d, 6.7) 
4‘ 18.9 1.06 (3H, d, 6.8) 
1‘‘ 25.7 
1.77 (1H, m) 
2.66 (1H, m) 
2‘‘ 119.7 4.76 (1H, t) 
3‘‘ 134.3  
4‘‘ 25.9 1.55 (3H, m) 
5‘‘ 18.1 1.66 (3H, s) 
1‘‘‘ 29.2 
1.93 (1H, m) 
2.05 (1H, m) 
2‘‘‘ 124.2 4.84 (1H, t) 
3‘‘‘ 133.0  
4‘‘‘ 25.8 1.66 (3H, s) 
5‘‘‘ 17.6 1.40 (3H, s) 
1‘‘‘‘ 35.8 
1.38 (1H, m) 
1.15 (1H, m) 
2‘‘‘‘ 22.5 
1.81 (1H, m) 
1.89 (1H, m) 
3‘‘‘‘ 123.8 5.02 (1H, t, 7.0) 
4‘‘‘‘ 132.0  
5‘‘‘‘ 17.7 1.57 (3H, m) 
6‘‘‘‘ 25.6 1.66 (3H, s) 
4-OH  18.57 (1H, s) 
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13C-NMR spectrum showed 31 carbons related to the measured probe. According to an 
HSQC spectrum, 11 carbons are referred as quaternary, 3 as =CH–, 2 as aliphatic methines, 5 
as –CH2– and 10 as –CH3 groups. A “down field shifted” signal at δH 18.57 ppm refers to the 
characteristic hydrogen bond between the hydroxyl group of the phloroglucinol main core 
and the keto group of the starter acid. The latter was unequivocally defined as activated 
isobutyric acid due to a very clear septet at δH 3.85 ppm (C-2’) and two doublets at δH 1.06 
ppm and 1.20 ppm, representing two –CH3 groups (C-3’, C-4’). 
Unusual high values of quaternary carbons in position 3 and 4 (δC 144.8 ppm and 194.3 ppm 
respectively) let suggesting the presence of an enol. Presence of a quaternary C-3 let 
suggesting the cyclisation appears between C-1→C-5 and not C-5→C-3. 
In the HMBC spectrum the protons of the –CH3 group (δH 1.32 ppm) are clearly correlated 
with both keto groups in the main phloroglucinol core (Fig. 65). This proved that the methyl 
group (C-10) is connected to C-1. 
Further HMBC correlations of the –CH3 group (δH 1.24 ppm, C-11) with quaternary carbon 
C-5 (δC 69.9 ppm) (Fig. 66) and lacking correlations with protons at C- 8, let to the suggestion 
that the cyclisation of an isoprene rest was realized from C-1 to C-5 and not vice versa. 
  
Fig. 65. Part of HMBC spectrum of 1: 
correlation between H-10 and C-2 and C-9. 
Fig. 66. Part of HMBC spectrum of 1: 
correlation between H-11 and C-5. 
 
Structure elucidation of substitution pattern regarding the isoprene chains started with the 
proton at ca. δH 5.00 ppm and were realized with the help of HMBC and COSY experiments. 
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Cross peaks between atoms in positions 1’’, 1’’’ and 1’’’’ helped connecting the aliphatic 
chains to the  phloroglucinol core in positions 5, 7 and 6 respectively. 
 
Fig. 67. Part of NOESY spectrum of 1: correlation between H-11 and H-7. 
 
NOESY experiments helped in defying relative stereochemistry (example, Fig. 67). Molecular 
formula was established as C31H47O4 by HRESIMS (m/z 483.3469 [M+H]
+). The hitherto not 
known compound was identified as (6S, 7S)-4-hydroxy-1,6-dimethyl-3-isobutyryl-5,7-bis(3-
methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-bicyclo-[3.3.1]non-3-ene-2,9-dione and was 
given a trivial name Triquetriborin. Experimental CD spectrum for 1 is presented on Fig. 68. 
 
 
Fig. 68. Experimental CD spectrum of 1. 
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Compounds 2 and 3 (Triquetrijakobin A and B) 
 
 
 
 
 
Tab. 12. 1H and 13C data in CDCl3 (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 (2) Triquetrijakobin A (3) Triquetrijakobin B 
C/H δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 168.8  168.8  
3 71.8  71.5  
4 92.4 4.71 (1H, dd, 8.5, 10.3) 92.4 4.74 (1H, t, 9.5) 
5 26.7 
2.86 (1H, m) 
26.6 2.90 (2H, dd, 4.5) 
2.96 (1H, m) 
6 108.0  108.0  
7 205.4  205.6  
8 56.3  56.4  
9 192.4  192.4  
10 100.3  100.3  
11 25.6 1.33 (3H, s) 25.9 1.33 (3H, s) 
12 24.5 1.25 (3H, m) 24.4 1.25 (3H, s) 
13 28.5 1.29 (3H, s) 28.8 1.30 (3H, s) 
1’ 197.9  197.7  
2’ 34.5 3.62 (1H, sept) 34.5 3.62 (1H, sept) 
3’ 20.6 1.23 (3H, d, 6.9) 19.6 1.23 (3H, d, 6.8) 
4’ 18.8 1.20 (3H, d, 6.7) 19.8 1.20 (3H, d, 6.8) 
1’’ 41.5 
2.06 (1H, dd, 3.3, 13.6) 
41.2 
2.08 (1H, m) 
2.19 (1H, m) 2.18 (1H, m) 
2’’ 46.6 1.97 (1H, m) 46.7 1.91 (1H, m) 
3’’ 136.4  137.0  
4’’ 126.3 4.85 (1H, t, 6.3) 125.8 4.82 (1H, t) 
5’’ 11.6 1.30 (3H, s) 11.6 1.32 (3H, s) 
6’’ 26.7 
2.18 (1H, m) 
26.7 
2.14 (1H, m) 
2.53 (1H, m) 2.55 (1H, m) 
7’’ 122.9 4.91 (1H, m) 122.9 4.90 (1H, m) 
8’’ 131.6  132.0  
9’’ 17.7 1.54 (3H, s) 17.8 1.53 (3H, s) 
10’’ 25.60 1.66 (3H, s) 25.6 1.64 (3H, s) 
11’’ 32.3 1.91 (2H, m) 32.4 1.90 (2H, m) 
12’’ 122.8 4.90 (1H, m) 122.8 4.88 (1H, m) 
13’’ 131.5  131.5  
14’’ 17.9 1.60 (3H, s) 17.9 1.54 (3H, s) 
15’’ 25.7 1.63 (3H, s) 25.7 1.62 (3H, s) 
9-OH  18.33 (s)  18.30 (s) 
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13C-NMR spectrum of 2 comprises 31 atoms, of which 11 carbons are quaternary, 6 are =CH–
, 4 are –CH2– and 10 –CH3 groups. A “down field shifted” signal at δH 18.33 ppm refers to the 
–OH group linked to the carbonyl group of the starter acid via hydrogen bond. Only one 
further keto group resonated at δc 205.4, indicating that the third oxygen of the main 
phloroglucinol core is either involved into a cyclization or an ether group. 
HMBC correlations proved the “3-ortho-pyrano” cyclisation type of this compound (Fig. 16, § 
1.1.4.2). Three isoprene rests, unusually connected to each other form an aliphatic side 
chain, connected to the main core in position 8. Starter acid was confirmed as activated 
isobutyric acid with a septet at δH 3.62 ppm for a methine proton and two doublets at δH 
1.20 ppm and δH 1.23 ppm for both –CH3 groups. 
Aliphatic side chain was confirmed according to HMBC and COSY experiments. Important to 
note is, that this substituent consists of two chains, a long (1’’ – 10’’) and a short one (11’’ – 
15’’). Although the long chain consists of 10 carbons, it is due to the displaced position of 
one double bond not a geranyl chain. Diagnostic correlations occur within the protons H-4’’, 
H-6’’ and H-7’’ (Fig. 69) thus confirming H-6’’ lies between two double bonds; in case of a 
geranyl side chain, this double bond would have lied between H-2’’and H-3’’. 
 
Fig. 69. Clip of COSY experiment of 3: correlation between H-4’’, H-6’’ and H-7’’. 
Carbon at position 4 has an unusually strong down field shift to δC 92.4 ppm, whereas the 
corresponding protons resonated at δH 4.71 ppm. Thus, oxygen was assumed to be 
connected to the carbon in position 4. Nevertheless no HMBC correlations showed any other 
atoms, which may lie beyond the hetero atom. It was suggested, that only an –OH group is 
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linked to the carbon in this position. This was later confirmed with a MS experiment, while 
evaluating the chemical formula of the substance. 
In elucidating the structure of compound 3, almost all the chemical shifts were the same, as 
for 2. Molecular mass of both compounds was confirmed the same. However, since both 2 
and 3 were isolated from one sub-fraction (PE-4.3) as two separate independent compounds 
(§ 3.1.2.3), they should possess different chemical structure. NOESY experiment showed that 
the difference is due to varying configuration at C-2’’. The differences in stereochemistry can 
be noted if comparing both spectra for 2 and 3 (Fig. 70 and 71). 
 
 
Fig. 70. Part of NOESY spectrum of 2: 
correlation between H-2’’ and H-4’’. 
Fig. 71. Part of NOESY spectrum of 3: 
correlation between H-4’’ and H-11’’. 
 
Experimental CD spectra for 2 and 3 are presented in Fig. 72 and Fig. 73 respectively. 
 
 
Fig. 72. Experimental CD spectrum of 2. Fig. 73. Experimental CD spectrum of 3. 
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Molecular formula for substance 2 was established as C31H47O5 by HRESIMS (m/z 499.3418 
[M+H]+). The compound was identified as the hitherto unknown (8S, 2’’S)-1-[3,3,8-trimethyl-
4,5,5-trihydro-4,9-dihydroxy-8-(3,7-dimethyl-2-(3-methylbut-2-en-1-yl)-octyl-3,6-diene)-
chroman-5-one-8-yl]-2-methylpropan-1-one and was given the trivial name Triquetrijakobin 
A. Molecular formula for substance 3 was established as C31H47O5 by HRESIMS (m/z 
499.3418 [M+H]+). The compound was identified as the hitherto unknown (8S, 2’’R)-1-[3,3,8-
trimethyl-4,5,5-trihydro-4,9-dihydroxy-8-(3,7-dimethyl-2-(3-methylbut-2-en-1-yl)-octyl-3,6-
diene)-chroman-5-one-8-yl]-2-methylpropan-1-one and was given the trivial name 
Triquetrijakobin B. 
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Compounds 4, 5 and 6 
(Triquetrireboudin A, B and C) 
 
 
 
 
Tab. 13. 1H and 13C data in CDCl3 
(1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 (4) Triquetrireboudin A (5) Triquetrireboudin B (6) Triquetrireboudin C 
C/H δC δH mult (J in Hz) δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 74.6  74.0  74.6  
2 171.8  171.7  171.9  
4 71.2  71.1  71.2  
5 93.3 4.66 (1H, t, 10.1) 93.9 4.78 (1H, t, 10.7) 93.5 4.62 (1H, t, 10.1) 
6 26.7 
2.90 (1H, dd, 10.3, 14.9) 
26.8 2.97 (2H, dd, 6.0, 10.6) 26.7 
2.90 (1H, dd, 10.2, 14.9) 
3.06, (1H, dd, 9.9, 14.9) 3.06 (1H, dd, 10.0, 14.9) 
7 119.8  120.3  119.9  
8 191.0  190.9  191.0  
9 59.8  60.1  59.9  
10 41.6 
1.29 (1H, m) 
41.4 
1.30 (1H, m) 
41.6 
1.29 (1H, m) 
1.93 (1H, dd, 4.5, 13.9) 1.93 (1H, dd, 4.0, 13.6) 1.93 (1H, dd, 4.5, 13.9) 
11 44.4 1.60 (1H, m) 42.3 1.71 (1H, m) 44.4 1.60 (1H, m) 
12 46.7  47.2  46.8  
13 206.5  206.3  206.5  
14 24.8 1.24 (3H, s) 25.3 1.25 (3H, s) 24.9 1.23 (3H, s) 
15 26.3 1.33 (3H, s) 26.6 1.37 (3H, s) 26.6 1.33 (3H, s) 
16 15.9 1.22 (3H, s) 15.9 1.22 (3H, s) 15.9 1.23 (3H, s) 
17 12.7 1.09 (3H, s) 14.5 1.13 (3H, s) 12.8 1.11 (3H, s) 
1‘ 209.0  208.8  208.4  
2‘ 40.7 2.41 (1H, m) 40.7 2.48 (1H, sept, 6.5) 47.6 2.16 (1H, m) 
3‘ 20.8 1.17 (3H, d, 6.5) 21.1 1.15 (3H, d, 6.5) 27.0 
1.35 (1H, m) 
1.71 (1H, m) 
4‘ 20.6 1.07 (3H, d, 6.5) 21.1 1.16 (3H, d, 6.5) 11.8 0.88 (3H, t, 7.5) 
5‘  17.0 1.17 (3H, d, 6.5) 
1‘‘ 39.1 
1.42 (1H, td, 4.0, 13.6) 
38.0 
1.59 (1H, m) 
39.2 
1.42 (1H, m) 
1.82 (1H, td) 1.66 (1H, m) 1.81 (1H, m) 
2‘‘ 25.2 
2.00 (1H, m) 
24.3 
1.94 (1H, m) 
25.2 
2.00 (1H, m) 
2.20 (1H, m) 2.02 (1H, m) 2.20 (1H, m) 
3‘‘ 124.3 5.00 (1H, t, 6.8) 124.3 4.99 (1H, t, 7.0) 124.3 5.00 (1H, t, 6.8) 
4‘‘ 132.2  131.6  132.2  
5‘‘ 17.8 1.59 (3H, s) 17.7 1.57 (3H, s) 17.8 1.59 (3H, s) 
6‘‘ 25.6 1.66 (3H, s) 25.6 1.65 (3H, s) 25.6 1.68 (3H, m) 
1‘‘‘ 27.8 
1.68 (1H, m) 
28.0 
1.71 (1H, m) 
27.0 
1.35 (1H, m) 
2.09 (1H, m) 2.08 (1H, m) 1.71 (1H, m) 
2‘‘‘ 122.2 4.91 (1H, t, 7.1) 122.2 4.94 (1H, t, 6.6) 122.2 4.91 (1H, m) 
3‘‘‘ 133.5  133.5  133.5  
4‘‘‘ 17.9 1.53 (3H, s) 18.0 1.55 (3H, s) 17.9 1.54 (3H, s) 
5‘‘‘ 28.5 1.66 (3H, s) 25.9 1.65 (3H, s) 25.8 1.74 (3H, m) 
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For 4 and 5 13C-NMR spectrum showed 31 atoms. Out of them, 11 carbons are quaternary, 5 
are methines, 5 are –CH2– and 10 –CH3 groups. Unlike in 1, 2 and 3, there were no “down 
field shifted” signals on 1H-NMR spectrum, which means no intramolecular hydrogen bond in 
this molecule exist and phloroglucinol main core oxygens are present as keto groups or 
involved in a cyclization. In 13C-NMR spectrum only three carbons resonated between 190 – 
207 ppm, one of which is referred to the starter acid, another two are in the main molecule 
core, while the third phloroglucinol oxygen is either etherized or cyclised. Cyclisation was 
confirmed as “3-ortho-pyrano” type (Fig. 16) with the same not detectable hydroxyl group in 
position 5, as described for 2 and 3. 
For substance 4 – a clear septet at δH 2.41 ppm (δC 40.7 ppm) for an aliphatic methin proton, 
as well as two doublets at δH 1.07 ppm and δH 1.17 ppm for –CH3 groups confirmed the 
starter acid as activated isobutyric acid. Two isoprene chains were evaluated with the help of 
HMBC and COSY experiments, starting from characteristic =CH– protons at δH 4.91 ppm and 
δH 5.00 ppm. Same way structures of 5 and 6 were elucidated with the only difference for 
the latter: its starter acid is 2-methylbutyryl with a pseudo-sextet at δH 2.16 ppm (δC 47.6 
ppm) for an aliphatic methine proton, as well as two –CH3 groups δH 1.17 ppm (doublet) and 
δH 0.88 ppm (triplet). 
Since 4 and 5 possess same structure, it was suggested, that the difference between two 
compounds lies in their different stereochemistry. Indeed, while almost all carbons have 
equal shift values (± 0.3-0.5 ppm), those for atoms C-11, C-17 and C-1’’ differ in both 
substances significantly: C-11 (δC 44.4 / 42.3 ppm), C-17 (δC 12.7 / 14.5 ppm) and C-1’’ (δC 
39.1 / 38.0 ppm) for 4 / 5 respectively. NOESY experiment confirmed the suggestion (Fig. 74-
76). 
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Fig. 74. Clip of NOESY experiment of 4: 
correlation between H-17 and H-1’’’. 
Fig. 75. Clip of NOESY experiment of 5: 
correlation between H-1’’’ and H-1’’. 
 
 
 
Fig. 76. Clip of NOESY experiment for 6: correlations between H-17 and H-11 (left) and 
correlations between H-3’’ and H-2’’’ (right). 
 
Molecular formula for substance 4 was established as C31H47O5 by HRESIMS (m/z 499.3418 
[M+H]+). The compound was identified as (11S, 12R)-1-isobutyryl-4,4,9,12-tetramethyl-11α-
(3-methylbut-2-enyl)-12-(4-methylpent-3-enyl)-3-oxatricyclo-[7.3.1.02,7]- trideca-2(7)-ene-
8,13-dione and was given a trivial name Triquetrireboudin A. Molecular formula for 
substance 5 was established as C31H47O5 by HRESIMS (m/z 499.3418 [M+H]+). The compound 
was identified as (11R, 12R)-1-isobutyryl-4,4,9,12-tetramethyl-11α-(3-methylbut-2-enyl)-12-
(4-methylpent-3-enyl)-3-oxatricyclo-[7.3.1.02,7]-trideca-2(7)-ene-8,13-dione and was given a 
trivial name Triquetrireboudin B. Molecular formula for substance 6 was established as 
C32H49O5 by HRESIMS (m/z 513.3575 [M+H]
+). The compound was identified as (11S, 12S)-1-
(2-methylbutanoyl)-4,4,9,12-tetramethyl-11α-(3-methyl-but-2-enyl)-12-(4-methylpent-3-
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enyl)-3-oxatricyclo-[7.3.1.02,7]trideca-2(7)-ene-8,13-dione and was given a trivial name 
Triquetrireboudin C. 
Experimental CD spectra for 4, 5 and 6 are presented in Fig. 77, 78 and 79 respectively. 
  
Fig. 77. Experimental CD spectrum of 4. Fig. 78. Experimental CD spectrum of 5. 
 
 
Fig. 79. Experimental CD spectrum of 6. 
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Compounds 7, 8 and 9 (Triquetrikotelin A, B and Triquetriroxettin) 
 
 
 
 
 
 
 
 
 
Tab. 14. 1H and 13C data in CDCl3  (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 (7) Triquetrikotelin A (8) Triquetrikotelin B (9) Triquetriroxettin 
C/H δC δH mult (J in Hz) δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 171.8  171.8  166.5  
3 72.7  72.6  72.6  
4 88.2 3.84 (1H, d, 9.7) 88.3 3.86 (1H, d, 9.7) 87.8 3.84 (1H, d, 9.5) 
5 23.6 
1.59 (1H, m) 
23.5 
1.59 (1H, m) 
24.2 
1.58 (1H, m) 
1.82 (1H, m) 1.82 (1H, m) 1.83 (1H, m) 
6 61.0  61.0  74.36  
7 33.4 
1.93 (1H, dd, 5.2, 14.9) 
33.4 
1.93 (1H, dd, 5.3, 15.0) 
33.2 
1.92 (1H, dd, 6.2, 13.8) 
2.53 (1H, m) 2.52 (1H, m) 2.54 (1H, m) 
8 36.6 2.09 (1H, m) 36.7 2.09 (1H, m) 36.9 2.04 (1H, m) 
9 44.9  45.0  45.0  
10 74.5  74.5  60.6  
11 195.6  195.6  194.5  
12 118.8 6.25 (1H, s) 118.7 6.25 (1H, s) 128.9  
13 207.2  207.2  207.2  
14 25.3 1.240 (1H, m) 25.3 1.24 (3H, s) 25.9 1.24 (3H, m) 
15 25.0 1.21 (3H, s) 24.9 1.21 (3H, s) 25.5 1.23 (3H, s) 
16 15.7 1.235 (3H, s) 15.7 1.23 (3H, s) 16.4 1.24 (3H, m) 
17 16.5 1.02 (3H, s) 16.6 1.02 (3H, s) 16.9 1.01 (3H, s) 
1‘ 210.9  210.1  211.5  
2‘ 41.1 2.52 (1H, sept) 47.9 2.26 (1H, sext) 41.0 2.51 (1H, sept) 
3‘ 21.6 1.18 (3H, d, 6.5) 26.7 
1.37 (1H, m) 
21.5 1.17 (3H, d, 6.5) 
1.69 (1H, m) 
4‘ 21.0 1.12 (3H, d, 6.5) 11.3 0.86 (3H, t, 7.4) 20.7 1.11 (3H, d, 6.6) 
5‘  17.5 1.17 (3H, d, 6.5)  
1‘‘ 42.8 
1.40 (1H, m) 
42.9 
1.39 (1H, m) 
42.8 
1.39 (1H, m) 
2.04 (1H, m) 2.04 (1H, m) 2.03 (1H, m) 
2‘‘ 26.9 
1.60 (1H, m) 
26.8 
1.59 (1H, m) 
26.7 
1.58 (1H, m) 
2.06 (1H, m) 2.06 (1H, m) 2.06 (1H, m) 
3‘‘ 121.8 4.95 (1H, t, 7.2) 121.8 4.95 (1H, t, 7.1) 121.8 4.93 (1H, m) 
4‘‘ 133.7  133.7  133.6  
5‘‘ 17.9 1.55 (3H, s) 17.9 1.54 (3H, s) 17.9 1.55 (3H, s) 
6‘‘ 25.8 1.67 (3H, s) 25.8 1.67 (3H, s) 25.8 1.67 (3H, s) 
1‘‘‘ 
 
22.8 
3.15 (1H, dd, 6.2, 15.1) 
 3.28 (1H, dd, 6.1, 15.1) 
2‘‘‘  121.8 4.96 (1H, m) 
3‘‘‘  133.6  
4‘‘‘  18.1 1.72 (3H, s) 
5‘‘‘  25.5 1.68 (3H, s) 
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The 13C-NMR spectrum of 7 showed 26 carbons, out of which 9 carbons are quaternary, 5 
are CH–, 4 are –CH2– and 8 –CH3 groups. Starter acid was confirmed as isobutyric acid with 
characteristic septet at δH 2.52 ppm and two doublets at δH 1.12 ppm and δH 1.18 ppm for its 
methyl groups. The substance has only one isoprene rest with =CH– proton at δH 4.95 ppm. 
The cyclisation type was confirmed as type-A 5-para-pyrano (Fig. 16) in an only possible way 
because of the presence of an aromatic proton in the main molecule’s core (δC 118.8 ppm, 
δH 6.25 ppm). 
Difference between 7 and 8 lies in its starter acid structure: isobutyryl versus 2-
methylbutyryl. In case of 8 a pseudo sextet resonated at δH 2.26 ppm characteristic for the 
methine proton, as well as a doublet at δH 1.17 ppm and triplet at δH 0.86 ppm for its both –
CH3 groups. 
Compound 9 is a derivative of 7, with isoprene chain connected to C-12 (δC 128.9 ppm), 
which is a quaternary one in this compound. The double bond remains between carbons C-1 
and C-12. 
Relative stereochemistry of these compounds was confirmed with NOESY experiments (Fig. 
80-82).  
  
Fig. 80. Clip of NOESY experiment of 7: 
correlation between H-16 and H-1’’. 
Fig. 81. Clip of NOESY experiment of 8: 
correlation between H-16 and H-1’’. 
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Fig. 82. Clip of NOESY experiment of 9: correlation between 
H-16 and H-1’’. 
 
Molecular formula of 7 was established as C26H39O5 by HRESIMS (m/z 431.2792 [M+H]
+). The 
compound was identified as (8S, 9S)-3,3,8,9-tetramethyl-9-(4-methylpent-3-enyl)-10-
isobutyryl-2-oxatricyclo[7.3.1.01,6]-trideca-1(12)ene-11,13-dione and Triquetrikotelin A was 
given as trivial name. Molecular formula for substance 8 was established as C27H41O5 by 
HRESIMS (m/z 445.2949 [M+H]+). The compound was identified as (8S, 9S)-3,3,8,9-
tetramethyl-9-(4-methylpent-3-enyl)-10-(2-methylbutanoyl)-2-oxatricyclo[7.3.1.01,6]-
trideca-1(12)ene-11,13-dione and was given a trivial name Triquetrikotelin B. Molecular 
formula for substance 9 was established as C31H47O5 by HRESIMS (m/z 499.3418 [M+H]
+). 
The compound was identified as (8S, 9S)-3,3,8,9-tetramethyl-9-(4-methylpent-3-enyl)-10-
isobutyryl-12-(3-methylbut-2-enyl)-2-oxatricyclo[7.3.1.01,6]-trideca-1(12)ene-11,13-dione 
and was and was trivially named Triquetriroxettin. 
Experimental CD spectra for compounds 7, 8 and 9 are shown on Fig. 83-85. 
  
Fig. 83. Experimental CD spectrum of 7. Fig. 84. Experimental CD spectrum of 8. 
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Fig. 85. Experimental CD spectrum of 9. 
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Compound 10 (Triquetribavarin) 
 
 
 
 
 
 
 
Tab. 15. 1H and 13C data in CDCl3  (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 
 
 
 
 
C/H δC δH mult (J in Hz) 
1 55.7  
2 203.5  
3 52.5 3.56 (1H, s) 
4 171.8  
5 173.4  
6 44.7  
7 37.9 2.74 (1H, m) 
8 38.0 
1.20 (1H, m) 
2.66 (1H, dd, 4.0, 14.2) 
9 72.4 3.82 (1H, s) 
10 208.6  
11 43.1 2.76 (1H, sept) 
12 18.5 1.10 (3H, d, 6.8) 
13 17.6 1.06 (3H, d, 7.0) 
14 18.9 0.78 (1H, s) 
15 37.4 
1.41 (1H, m) 
1.51 (1H, m) 
16 22.5 
1.62 (1H, m) 
1.85 (1H, m) 
17 123.9 4.95 (1H, t, 13.8) 
18 131.8  
19 26.6 1.65 (3H, s) 
20 17.7 1.54 (3H, s) 
21 27.8 
1.62 (1H, m) 
2.20 (1H, m) 
22 123.3 5.22 (1H, m) 
23 132.4  
24 25.8 1.74 (3H, s) 
25 18.0 1.60 (3H, s) 
26 23.5 1.27 (3H, s) 
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Substance 10 was isolated in a very low quantity (< 0.6 mg) and 13C-NMR didn’t show all 
quaternary carbons. Several carbons were allocated with the help of HMBC experiment and 
added to the list manually. Therefore, 26 carbon atoms were detected, out of which 8 are 
quaternary, 6 are methines, 4 are –CH2– and 8 –CH3 groups. Two isoprene chains elucidation 
started with characteristic protons at δH 5.22 ppm and δH 4.95 ppm. Further correlations 
within the chains and their connections to the molecule’s main core were established with 
the help of HMBC and COSY experiments. Starter acid was confirmed as isobutyric acid, with 
a characteristic septet at δH 2.76 ppm (δC 43.1 ppm) for an aliphatic CH proton, as well as 
two doublets δH 1.10 ppm and δH 1.06 ppm for its both –CH3 groups. Two down field shifted 
carbons (δC 203.5 ppm and δC 171.8 ppm) represent two keto groups in positions 2 and 4 
respectively. C-3 (δC 52.5 ppm, δH 3.56 ppm) and C-9 (δC 72.4 ppm, δH 3.82 ppm) are CH– 
groups near an oxygen, because of the down field shifted values (Fig. 86). No hydroxyl group 
exist in this compound, especially as the corresponding “down field shifted” singlet of a 
proton is absent in the 1H-NMR spectrum. 
 
Fig. 86. HSQC correlations between between C-H atoms at C-3 and C-9. 
 
Relative stereochemistry for 10 was confirmed with NOESY experiment (Fig. 87). 
Experimental CD spectrum for 10 is shown in Fig. 88. 
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Fig. 87. Clip of NOESY experiment of 10. 
 
Molecular weight for substance 10 was established by HRESIMS (m/z 415.2115 [M+H]+), 
which is in accordance with the postulated chemical formula C26H28O4.  The compound was 
identified as (1R, 3S, 5R, 6R, 7S, 9S)-1,6-dimethyl-5-isobutyryl-6-(4-methylpent-3-enyl)-7-(3-
methylbut-2-enyl)-bicyclo-[3.3.1]-3,9-epoxy-3,9-dihydro-2,4-dione and was given a trivial 
name Triquetribavarin. 
 
Fig. 88. Experimental CD spectrum of 10. 
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3.1.3.3 Possible hyperforin analogues and precursors 
Compound 11 and 12 ((+)-Yezo’otogirin C and Triquetriirinon A) 
 
 
 
 
 
Tab. 16. 1H and 13C data in CDCl3  (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (11) (+)-Yezo’otogirin C (12) Triquetriirinon A 
C/H δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 149.3  210.6  
2 73.6  66.7 3.85 (1H, s) 
3 48.5  45.5  
4 47.0 1.23 (1H, m) 42.4 1.84 (1H, m) 
5 32.7 
1.86 (1H, dd, 3.4, 15.5) 
36.9 
1.22 (1H, dd, 12.8) 
1.95 (1H, m) 2.11 (1H, m) 
6 107.5  45.5 2.46 (1H, m) 
7 217.5  211.0  
8 38.0 2.96 (1H, sept, 6.7) 42.7 2.47 (1H, m) 
9 18.3 1.02 (3H, d, 6.5) 17.7 1.06 (3H, d, 6.7) 
10 21.5 1.01 (3H, d, 6.8) 18.5 1.04 (3H, d, 7.0) 
11 19.7 0.75 (3H, s) 17.3 1.00 (3H, s) 
12 41.5 
1.35 (1H, m) 
36.6 1.48 (2H, m) 
1.74 (1H, m) 
13 25.4 1.54 (2H, m) 21.9 
1.80 (1H, m) 
2.05 (1H, m) 
14 54.9 3.19 (1H, dd, 8.9, 9.9) 123.7 4.98 (1H, t, 6.9) 
15 83.5  131.7  
16 25.4 1.18 (3H, s) 17.6 1.58(3H, s) 
17 29.5 1.14 (3H, s) 25.7 1.66 (3H, s) 
18 29.6 
1.82 (1H, m) 
26.8 
1.70 (1H, m) 
1.94 (1H, m) 2.10 (1H, m) 
19 124.2 5.11 (1H, t, 7.2) 123.0 5.11 (1H, t, 7.2) 
20 132.4  132.9  
21 17.9 1.60 (3H, s) 17.9 1.61 (3H, s) 
22 25.9 1.72 (3H, s) 25.9 1.73 (3H, s) 
23 16.3 1.71 (3H, s) 14.3 1.01 (3H, d, 6.4) 
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13C-NMR spectrum for compound 11 showed 23 carbons, out of which 7 are quaternary, 4 
are methines, 4 are –CH2– and 8 –CH3 groups. Starter acid was confirmed as isobutyric acid 
with an aliphatic CH– proton at δH 2.96 ppm and two doublets at δH 1.01 ppm and δH 1.02 
ppm as both –CH3 groups. The presence of only one isoprene rest was confirmed with both 
HMBC and COSY experiments, starting from its =CH– proton at δH 5.11 ppm. 
Main core of the molecule was elucidated as octahydroindeno[7,1-bc]furan with four methyl 
groups. Example of HMBC correlations can be observed from Fig. 89. 
 
Fig. 89. Clip of HMBC experiment of 11: example correlations. 
Original article describing the first ever elucidation of Yezo’otogirin C (Tanaka et al., 2009) 
provides molecule atoms’ numbering only and does not provide any IUPAC name for the 
substance. Following articles, which describe Yezo’otogirin C and its possible biosynthesis, 
etc. (He et al., 2014; Yang et al., 2015a) use only a trivial name of the compound and follow 
the same atoms’ numbering, as was suggested in the original paper by Tanaka et al. In 
course of the present work Tab. 16 refers to and still maintains the original numbering for 
comparison reasons. However, Fig. 90 presents alternative numbering and the IUPAC name 
for 11: (2aS, 2a1R, 4aS, 5S)-2a1-isobutyryl-2,2,4a,7-tetramethyl-5-(3-methylbut-2-enyl)-
2,2a,2a1,3,4,4a,5,6-octahydroindeno[7,1-bc]furan. 
98 | R e s u l t s  a n d  D i s c u s s i o n  
 
Fig. 90. (+)-Yezo’otogirin C. 
Carbon spectrum for 12 comprises 23 carbons as well, out of which 5 are quaternary, 6 are 
=CH–, 4 are –CH2– and 8 –CH3 groups. Both isoprene rests were elucidated with HMBC and 
COSY experiments help, starting from their =CH– protons (δH 4.98 ppm and δH 5.11 ppm). 
Starter acid was detected as activated isobutyric acid, because of its septet (δC 42.7 ppm, δH 
2.47 ppm) and two doublets (δH 1.04 ppm, δH 1.06 ppm) for its –CH3 groups. The only keto 
group in the main core is proved by a down shifted carbon at δC 210.6 ppm. 
Stereochemistry was defined according to NOESY spectra (Fig. 91-92). 
  
Fig. 91. Clip of NOESY experiment of 11. Fig. 92. Clip of NOESY experiment of 12. 
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For a better understanding of stereochemistry of 11, a tridimensional model was build and is 
presented on Fig. 93 below. 
 
Fig. 93. Modeled structure of 11. 
 
Experimental CD spectra for 11 and 12 are presented on Fig. 94 and Fig. 95 respectively. 
  
Fig. 94. Experimental CD spectrum of 11. Fig. 95. Experimental CD spectrum of 12. 
 
Molecular formula for substance 11 was established as C23H37O2 by HRESIMS (m/z 345.2788 
[M+H]+). Molecular formula for substance 12 was established as C23H39O2 by HRESIMS (m/z 
347.2945 [M+H]+). The compound was identified as 2-isobutyryl-3,6-dimethyl-3-(4-
methylpent-3-en-1-yl)-4-(3-methylbut-2-en-1-yl)-cyclohexan-1-one. It was isolated for the 
first time and given the trivial name Triquetriirinon A. 
100 | R e s u l t s  a n d  D i s c u s s i o n  
Compounds 13, 14 and 15 (Triquetriirinon B, C and D) 
 
  
 
 
 
 
 
Tab. 17. 1H and 13C data in CDCl3  (
1H-NMR 600 MHz, 13C-NMR 150 MHz, 298 K) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (13) Triquetriirinon B (14) Triquetriirinon C (15) Triquetriirinon D 
C/H δC δH mult (J in Hz) δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 203.5  210.7  209.0  
2 72.4 3.82 (1H, m) 67.1 3.83 (1H, s) 61.4 4.67 (1H, s) 
3 55.7  45.6  45.8  
4 37.9 2.74 (1H, m) 42.5 1.83 (1H) 37.6 2.10 (1H, m) 
5 37.4 
1.41 (1H, m) 
36.9 
1.21 (1H) 
42.2 
1.44 (1H, m) 
1.50 (1H, m) 2.10 (1H) 2.01 (1H, m) 
6 44.7  45.55 2.46 (1H, m) 75.6  
7 208.5  210.5  211.2  
8 43.1 2.76 (1H, m) 49.6 2.29 (1H, sext) 42.7 2.48 (1H, sept) 
9 17.6 1.06 (3H, d, 6.8) 25.4 
1.26  (1H, m) 
17.7 1.07 (1H, d, 6.9) 
1.64 (1H, m) 
10 18.5 1.10 (3H, d, 6.9) 11.5 0.88 (3H, t, 7.4) 18.5 1.06 (1H, d, 7.0) 
11 23.5 1.27 (3H, s) 14.5 1.04 (3H, d, 6.8) 16.5 0.99 (3H, s) 
12 38.0 
1.20 (1H, m) 
17.3 1.00 (3H, m) 36.7 1.50 (2H, m) 
2.66 (1H, dd, 4.0, 14.3) 
13 27.8 
1.61 (1H, m) 
36.6 1.48 (2H, m) 22.0 
1.83 (1H, m) 
2.19 (1H, m) 2.07 (1H, m) 
14 123.3 5.22 (1H, m) 21.9 
1.80 (1H, m) 
123.7 4.98 (1H, t) 
2.06 (1H, m) 
15 132.4  123.6 4.97 (1H, m) 131.7  
16 18.0 1.61 (3H, m) 131.7  17.7 1.58 (3H, s) 
17 25.8 1.74 (3H, s) 17.7 1.56 (3H, s) 25.7 1.66 (3H, s) 
18 22.5 
1.63 (1H, m) 
25.7 1.66 (3H, s) 26.5 
1.65 (1H, m) 
1.85 (1H, m) 2.10 (1H, m) 
19 123.9 4.95 (1H, m) 26.8 
1.70 (1H, m) 
122.8 5.10 (1H, t) 
2.11 (1H, m) 
20 131.8  123.0 5.11 (1H, t, 7.1) 132.9  
21 17.7 1.54 (3H, m) 132.9  18.0 1.60 (3H, s) 
22 25.6 1.65 (3H, s) 18.0 1.61 (3H, s) 25.9 1.73 (3H, s) 
23 18.9 0.78 (3H, s) 25.9 1.73 (3H, s) 23.9 1.30 (3H, brs) 
24  14.3 1.01 (3H, d, 6.4)  
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Compound 13 was not separable from 12 and thus elucidated only in a mixture. The signals 
were separated and therefore the elucidation of both structures from one set of NMR 
spectra was possible. The only difference between 12 and 13 lie in the fact that substituents 
(methyl group and prenyl side chain) in positions 4 and 6 are reversed. Compound 14 differs 
from 12 in its starter acid: activated 2-methyl-butyric acid versus isobutyric acid. In this case 
for 14, a =CH– group proton is shown as a multiplet (probably an overlaid pseudo sextet) (δH 
2.29 ppm), while one –CH3 group resonated as a doublet (δH 1.04 ppm) and another as a 
triplet (δH 0.88 ppm). 
Stereochemistry for 14 was confirmed in NOESY experiments (Fig. 96). 
  
Fig. 96. Clip of NOESY experiment of 14: most important correlations. 
 
Substance 15 has an additional hydroxyl group in position 6: C-6 is quaternary and resonates 
at δC 75.6 ppm. The proton of the –OH group didn’t show any signals in 
1H-NMR spectrum, 
but its presence was confirmed with MS experiment. Several basic HMBC correlations can be 
observed from Fig. 97. 
Stereochemistry of 15 was defined with NOESY experiment (Fig. 98). Experimental CD 
spectra for 14 and 15 are presented in Fig. 99 and 100. 
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Fig. 97. Clip of HMBC experiment of 15: 
several important HMBC correlations. 
Fig. 98. Clip of NOESY experiment of 15: 
correlations between H-2 and H-4 and H-11. 
 
  
Fig. 99. Experimental CD spectrum of 14. Fig. 100. Experimental CD spectrum of 15. 
 
Molecular formula for substance 12 was established as C23H39O2 by HRESIMS (m/z 347.2945 
[M+H]+). The compound was identified as 2-isobutyryl-3,4-dimethyl-3-(4-methylpent-3-en-1-
yl)-6-(3-methylbut-2-en-1-yl)-cyclohexan-1-one and was given a trivial name Triquetriirinon 
B. Molecular formula for substance 13 was established as C24H41O2 by HRESIMS (m/z 
361.3101 [M+H]+). The compound was identified as (2R, 3R, 4S, 6R)-2-(2-methylbutanoyl)-
3,6-dimethyl-3-(4-methylpent-3-en-1-yl)-4-(3-methylbut-2-en-1-yl)-cyclohexan-1-one and 
was given a trivial name Triquetriirinon C. Molecular formula for substance 14 was 
established as C23H39O3 by HRESIMS (m/z 363.2894 [M+H]
+). The compound was identified as 
(2R, 3R, 4S, 6S)-2-isobutyryl-3,6-dimethyl-3-(4-methylpent-3-en-1-yl)-4-(3-methylbut-2-en-1-
yl)-6-hydroxy-cyclohexan-1-one. The hitherto unknown compound was given the trivial 
name Triquetriirinon D. 
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3.1.4 Overview of the isolated substances 
3.1.4.1 Prenylated acylphloroglucinols 
The data presented in this list are: trivial name, IUPAC-name; state of matter (isolated quantity); 
specific rotation (concentration [g/100 ml], solvent); UV wave length (molar attenuation coefficient’s 
logarithm); NMR data; MS data. 
 
1 – Triquetriborin 
(6S, 7S)-4-hydroxy-1,6-dimethyl-3-isobutyryl-5,7-bis(3-
methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-bicyclo-
[3.3.1]non-3-ene-2,9-dione 
 
Green oil (1.46 mg); [α]23D +30 (c 0.01, MeOH); UV (MeOH) 
λmax (log ε) 285 (2.92) nm; 
1H- and 13C-NMR data see Tab. 11; 
HRESIMS m/z 483.3463 [M+H]+ (calculated for C31H47O4, 
483.3469) 
 
2 – Triquetrijakobin A 
(8S, 2’’S)-1-[3,3,8-trimethyl-4,5,5-trihydro-4,9-dihydroxy-8-
(3,7-dimethyl-2-(3-methylbut-2-en-1-yl)-octyl-3,6-diene)-
chroman-5-one-8-yl]-2-methylpropan-1-one 
 
Green oil (3.36 mg); [α]23D -21 (c 0.05, MeOH); UV (MeOH) 
λmax (log ε) 269 (3.62), 314 (3.48) nm; 
1H- and 13C-NMR data 
see Tab. 12; HRESIMS m/z 499.3423 [M+H]+ (calculated for 
C31H47O5, 499.3418) 
 
3 – Triquetrijakobin B 
(8S, 2’’R)-1-[3,3,8-trimethyl-4,5,5-trihydro-4,9-dihydroxy-8-
(3,7-dimethyl-2-(3-methylbut-2-en-1-yl)-octyl-3,6-diene)-
chroman-5-one-8-yl]-2-methylpropan-1-one 
 
Green oil (3.30 mg); [α]23D +140 (c 0.05, MeOH); UV (MeOH) 
λmax (log ε) 272 (3.63), 315 (3.55) nm; 
1H- and 13C-NMR data 
see Tab. 12; HRESIMS m/z 499.3420 [M+H]+ (calculated for 
C31H47O5, 499.3418) 
 
4 – Triquetrireboudin A 
(11S, 12R)-1-isobutyryl-4,4,9,12-tetramethyl-11α-(3-
methylbut-2-enyl)-12-(4-methylpent-3-enyl)-3-oxatricyclo-
[7.3.1.02,7]- trideca-2(7)-ene-8,13-dione 
 
Greenish oil (10.95 mg); [α]23D +118 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 280 (4.18) nm; 
1H- and 13C-NMR data see 
Tab. 13; HRESIMS m/z 499.3418 [M+H]+ (calculated for 
C31H47O5, 499.3418) 
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5 – Triquetrireboudin B 
(11R, 12R)-1-isobutyryl-4,4,9,12-tetramethyl-11α-(3-
methylbut-2-enyl)-12-(4-methylpent-3-enyl)-3-oxatricyclo-
[7.3.1.02,7]-trideca-2(7)-ene-8,13-dione 
 
Greenish oil (29.21 mg); [α]23D +166 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 280 (3.48) nm; 
1H- and 13C-NMR data see 
Tab. 13; HRESIMS m/z 499.3425 [M+H]+ (calculated for 
C31H47O5, 499.3418) 
 
6 – Triquetrireboudin C 
(11S, 12S)-1-(2-methylbutanoyl)-4,4,9,12-tetramethyl-11α-
(3-methyl-but-2-enyl)-12-(4-methylpent-3-enyl)-3-
oxatricyclo-[7.3.1.02,7]trideca-2(7)-ene-8,13-dione 
 
Greenish oil (1.19 mg); [α]23D -60 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 280 (3.88) nm; 
1H- and 13C-NMR data see 
Tab. 13; HRESIMS m/z 513.3577 [M+H]+ (calculated for 
C32H49O5, 513.3575) 
 
7 – Triquetrikotelin A 
(8S, 9S)-3,3,8,9-tetramethyl-9-(4-methylpent-3-enyl)-10-
isobutyryl-2-oxatricyclo[7.3.1.01,6]-trideca-1(12)ene-11,13-
dione 
 
Greenish oil (4.52 mg); [α]23D -138 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 270 (3.58) nm; 
1H- and 13C-NMR data see 
Tab. 14; HRESIMS m/z 431.2796 [M+H]+ (calculated for 
C26H39O5, 431.2792) 
 
8 – Triquetrikotelin B 
(8S, 9S)-3,3,8,9-tetramethyl-9-(4-methylpent-3-enyl)-10-(2-
methylbutanoyl)-2-oxatricyclo[7.3.1.01,6]-trideca-1(12)ene-
11,13-dione 
 
Greenish oil (1.54 mg); [α]23D -104 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 270 (3.40) nm; 
1H- and 13C-NMR data see 
Tab. 14; HRESIMS m/z 445.2952 [M+H]+ (calculated for 
C27H41O5, 445.2949) 
 
9 – Triquetriroxettin 
(8S, 9S)-3,3,8,9-tetramethyl-9-(4-methylpent-3-enyl)-10-
isobutyryl-12-(3-methylbut-2-enyl)-2-oxatricyclo[7.3.1.01,6]-
trideca-1(12)ene-11,13-dione 
 
Greenish oil (2.24 mg); [α]23D -116 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 275 (3.97) nm; 
1H- and 13C-NMR data see 
Tab. 14; HRESIMS m/z 499.3424 [M+H]+ (calculated for 
C31H47O5, 499.3418) 
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10 – Triquetribavarin 
(1R, 3S, 5R, 6R, 7S, 9S)-1,6-dimethyl-5-isobutyryl-6-(4-
methylpent-3-enyl)-7-(3-methylbut-2-enyl)-bicyclo-[3.3.1]-
3,9-epoxy-3,9-dihydro-2,4-dione 
 
Greenish oil (0.59 mg); [α]23D -58 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 280 (3.22) nm; 
1H- and 13C-NMR data see 
Tab. 15 
 
 
3.1.4.2 Possible hyperforin analogues and precursors 
 
11 – (+)-Yezo’otogirin C 
(2aS, 2a1R, 4aS, 5S)-2a1-isobutyryl-2,2,4a,7-
tetramethyl-5-(3-methylbut-2-enyl)-
2,2a,2a1,3,4,4a,5,6-octahydroindeno[7,1-bc]furan 
 
Colourless oil (14.53 mg); [α]23D +56 (c 0.01, MeOH); UV 
(MeOH) λmax (log ε) 275 (3.34) nm; 
1H- and 13C-NMR data see 
Tab. X; HRESIMS m/z 345.2787 [M+H]+ (calculated for 
C23H37O2, 345.2788) 
 
12 – Triquetriirinon A 
(2R, 3R, 4S, 6R)-2-isobutyryl-3,6-dimethyl-3-(4-methylpent-3-
en-1-yl)-4-(3-methylbut-2-en-1-yl)-cyclohexan-1-one 
 
Colourless or slightly greenish oil; [α]23D +170 (c 0.01, 
MeOH); UV (MeOH) λmax (log ε) 289 (3.36) nm; 
1H- and 13C-
NMR data see Tab. 16; HRESIMS m/z 347.2950 [M+H]+ 
(calculated for C23H39O2, 347.2945) 
 
 
13 – Triquetriirinon B 
2-isobutyryl-3,4-dimethyl-3-(4-methylpent-3-en-1-yl)-6-(3-
methylbut-2-en-1-yl)-cyclohexan-1-one 
 
Colourless oil; substance elucidated only in a mixture with 
(12); 1H- and 13C-NMR data see Tab. 17; HRESIMS m/z 
347.2948 [M+H]+ (calculated for C23H39O2, 347.2945) 
 
14 – Triquetriirinon C 
(2R, 3R, 4S, 6R)-2-(2-methylbutanoyl)-3,6-dimethyl-3-(4-
methylpent-3-en-1-yl)-4-(3-methylbut-2-en-1-yl)-cyclohexan-
1-one 
 
Greenish oil (3.25 mg); [α]23D -60 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 275 (2.91) nm; 
1H- and 13C-NMR data see 
Tab. 17; HRESIMS m/z 361.3102 [M+H]+ (calculated for 
C24H41O2, 361.3101) 
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15 – Triquetriirinon D 
(2R, 3R, 4S, 6S)-2-isobutyryl-3,6-dimethyl-3-(4-methylpent-3-
en-1-yl)-4-(3-methylbut-2-en-1-yl)-6-hydroxy-cyclohexan-1-
one 
 
Greenish oil (0.64 mg); [α]24D +38 (c 0.05, MeOH); UV 
(MeOH) λmax (log ε) 280 (3.21) nm; 
1H- and 13C-NMR data see 
Tab. 17; HRESIMS m/z 363.2899 [M+H]+ (calculated for 
C23H39O3, 363.2894) 
 
3.1.4.3 Other compounds 
In addition to the above described substances, other substances were also isolated from H. 
triquetrifolium in course of the present work. They are: two fatty acids and three flavonoids. 
All these compounds were previously isolated from the species and are therefore known to 
be present in the plant. 
16 – α-Linolenic acid (ω-3, C18:3) 
 
17 – Linoleic  acid (ω-6, C18:2) 
 
 
18 – Rutin 
Quercetin-3-O-rutinoside 
19 – Astragalin 
Kaempferol 3-O-glucoside 
20 – Hyperoside 
Quercetin-3-O-galactoside 
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3.1.5 Discussion of isolation and structure elucidation 
Compound 1 (Triquetriborin) refers to type B(I) acylphloroglucinol (Fig. 15). However, 
according to (Dakanali and Theodorakis, 2011) type B(I) compounds have got a quaternary 
carbon and two methyl groups, attached to it in position 8 as in clusianone, unlike 
Triquetriborin (Fig. 101). 
 
Fig. 101. Comparison of structures of Triquetriborin and Clusianone. 
Compounds of B(I) type were previously reported in Hypericum herbs, belonging to sections 
17, 20, 26, 27 and sub-section 9c (Schmidt and Heilmann, 2013). The latter comprises one 
representative, H. sampsonii, which accumulates clusianone (Hu and Sim, 2000) (Fig. 101). 
This is the first ever report of type B(I) acylphloroglucinol presence in Hypericum, belonging 
to section 9. This also confirms chemotaxonomic relations between herbs from sections 9 
and 9c. Therefore, the first principal difference between 1 and clusianone lies in the 
character of the starter acid (aliphatic or aromatic), type of main core structure cyclisation 
and stereo configuration. The main structural difference regarding the carbon skeleton is the 
ring closing from C-1 to C-5 which started in clusianone most probably from a precursor 
substituted at C-5 with two prenyl rests, whereas the precursor of triquetriborin started 
from a prenyl group substituted at C-1. 
Compounds 2 and 3 (Triquetrijakobin A and B) are bicyclic acylphloroglucinols with 3-ortho-
pyrano cyclisation type (Fig. 16). They both have a hydroxyl group in the main core, which 
builds a hydrogen bond with the oxygen of a starter acid’s keto group. These compounds 
possess a specific and unusual aliphatic side chain, built of three isoprene rests: it consists of 
a “long chain” (1’’ – 10’’) and a “short chain” (11’’ – 15’’). The long chain consists of 10 
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carbons, but it is not a geranyl rest. Each separate isoprene rest is numbered in blue, red and 
black for better overview (Fig. 102). This unusual aliphatic side chain discovered during this 
work shall receive a trivial name “evgenyl”. 
 
Fig. 102. Overview of Triquetrijakobin A’s aliphatic side chain. 
Compound with similar structure was isolated from H. erectum (Ishida et al., 2010) (section 
9), and is called otogirinin G (Fig. 103). This compound has similar main core (hydroxyl group 
in position 7 instead of keto group in Triquetrijakobins), but differs in aromatic starter acid 
and geranyl rest in position 8. The structural similarity of both secondary metabolites 
isolated from two species of the same section once again proves the chemotaxonomical 
relation between both species. 
 
Fig. 103. Structural formula of Orotiginin G, isolated from H. erectum (section 9). 
Compounds 4, 5 and 6 (Triquetrireboudin A, B and C) belong to type A 3-ortho-pyrano 
polycyclic acylphloroglucinols (Fig. 15 and 16). Their structure reminds hyperforin a lot (Fig. 
11) with only two differences: methyl group in position 9 instead of an isoprene, as well as 
cyclised isoprene in position 7. Thus these compounds might possess high biological activity 
like hyperforin itself, what has to be proven in further assays. 
Compounds 7, 8 and 9 (Triquetrikotelin A, B and Triquetriroxettin) are also type A polycyclic 
acylphloroglucinols, but their cyclisation happens to form a rare 5-para-pyrano system (Fig. 
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16). All three compounds are very much the same, with the only difference in 8: 2-
methylbutyric acid as a starter acid and 9: isoprene chain in position 12. 
Compound 10 (Triquetribavarin) is a type A polycyclic acylphloroglucinol with 7-
oxabicyclo[2.2.1]heptane-2,6-dione core. This structure is unusual, however already known: 
at least two substances with the similar configuration were previously isolated (Fig. 104). An 
oxidated hyperforin analogue 8-hydroxyhyperforin 8,1-hemiacetal was isolated from H. 
perforatum (section 9) (Verotta et al., 2000). Hyperfoliatin was first isolated from H. 
perfoliatum (section 13) (Benkiki et al., 2003); a year later the same substance was also 
isolated under the name “Hyperibone J” from H. scabrum (section 17) (Tanaka et al., 2004). 
These two compounds are oxidated hyperforin analogues. Hyperibine J isolated from H. 
triquetrifolium (Mitsopoulou et al., 2015) is an obvious precursor of hyperibone J, which in 
turn can be a precursor of 10. 
 
 
Fig. 104. Comparison of structural similarities between 8-hydroxyhyperforin 8,1-hemiacetal, 
Hyperibine J, Hyperibone J (Hyperfoliatin) and Triquetribavarin. 
 
(-)-Yezo’otogirin C was first-ever isolated from H. yezoense MAXIM. (Tanaka et al., 2009). This 
herb belongs to Section 9 along with H. perforatum and H. triquetrifolium (§ 1.1.2, Fig. 2). 
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Fig. 105. Proposed theories of yezo’otogirin A and C biosynthesis 
(Tanaka et al., 2009; He et al., 2014). 
 
Compound depicted on Fig. 105, a was first-ever isolated from H. perforatum as a 
hyperforine analogue (Shan et al., 2001) and later also from H. yezoense alongside 
yezo’otogirins A-C (Tanaka et al., 2009). Tanaka et al. suggested a plausible biogenetic 
pathway, where yezo’otogirin A derives from (a) via an intramolecular cyclization (Fig. 105, 
(I)). 
Inspired by this idea, a group of Chinese scientists developed a biomimetic synthesis of (±)-
yezo’otogirin C via an oxidative cascade cyclization (He et al., 2014). A substrate (Fig. 105, b) 
was initially synthesized from 3-methyl-4-isoprene-cyclohex-2-en-1-one. Since the originally 
proposed synthesis was conducted via 2 pathways, one of which led to formation of highly 
instable intermediates, the same working group improved their theory and presented 
another vision of the same process (Yang et al., 2015a). In the latter case, the substrate 
synthesis is suggested from cyclohexane-1,3-dione and biomimetic pathways to 
yezo’otogirin C were investigated under aerobic and anaerobic conditions, both are found to 
be feasible pathways to the natural product depending on the physiological conditions. A 
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shortened scheme of the improved yezo’otogirin C biosynthesis theory is presented in Fig. 
106. 
 
Fig. 106. Schematic biosynthesis theory of Yezo’otogirin C (Yang et al., 2015a). 
Therefore, the initial substrates for yezo’otogirins A and C (Fig. 105) differ in substituents in 
position 6 – isoprene- or methyl-group respectively. The substrate for yezo’otogirin A was 
isolated from the living plant, while the one for yezo’otogirin C was synthesised organically. 
In the course of this work, substance (Fig. 105, b) was isolated from the living herb for the 
first time. It was isolated from a sub-fraction close to that, from which yezo’otogirin C was 
isolated as well. This confirms the suggestion of He et al. and proves that (Fig. 105, b) which 
received a trivial name of Triquetriirinon A in the course of the present work, must really be 
a biosynthetic precursor of yezo’otogirin C, one of the main constituents of several 
Hypericum herbs of section 9. 
It should be also noted, that unlike isolated from H. yezoense (-)-yezo’otogirin C, the one 
isolated from H. triquetrifolium possesses different stereo configuration, according to its 
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NOESY spectra and is (+)-yezo’otogirin C. According to the literature research, this is the first 
report of a (+)-yezo’otogirin C isolation from a living herb. 
A group of substances 12-15 (Triquetriirinons A-D) was also isolated from H. triquetrifolium 
for the first time. Compound 13 (Triquetriirinon B) was only isolated in a mixture with 12. 
The only difference between 12 and 13 is the reversed position of an isoprene rest and a 
–CH3 group. Chemical 14 differs from 12 in a character of its starter acid, while 15 does also 
possess a hydroxyl group in position 6. All these compounds are believed to be 
phloroglucinol analogues and/or precursors. 
Biosynthesis of 15 is believed to be mostly the same as for acylphloroglucinols, with the only 
one difference: malonate and acetate react with each other in this case in ratio 1:1 (Fig. 
107). 
 
Fig. 107. Proposed biosynthesis of Triquetriirinon D; inspired by (Gao et al., 2016). 
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Omega-3 and omega-6 fatty acids are rare in herbs, however known for several 
representatives of the genus Hypericum. Acids 16 (α-Linolenic) and 17 (Linoleic) were 
isolated by (Hosni et al., 2007). Flavonoid 18 (Rutin) was described in H. triquetrifolium by 
(Cirak et al., 2011) while 19 (Astragalin) and 20 (Hyperoside) were found in this herb by 
(Conforti et al., 2002). 
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3.1.6 Conclusion and summary on phytochemical experiments 
Hypericum triquetrifolium TURRA belongs to section 9 along with H. perforatum, the most 
famous and widely used today representative of the genus. Several studies were conducted 
on H. triquetrifolium’s phenolic constituents and its essential oil composition; however its 
acylphloroglucinol spectrum was poorly explored. 
For this purpose, H. triquetrifolium was collected in summer 2012 on Golan Heights, Israel 
from wild nature. It was dried and subsequently extracted with different solvents. Petroleum 
ether extract was separated using various chromatographic methods (CPC, Flash column 
chromatograph, RP-HPLC), yielding in 17 compounds: 10 acylphloroglucinols, 5 hyperforin 
analogues and 2 fatty acids. Also 3 flavonoids from methanolic extract were obtained. 
All isolated acylphloroglucinols are new, previously unknown compounds. They belong to 
different phloroglucinol types, characteristic for section 9, therefore, confirming taxonomic 
relationship between species. Moreover, a compound of type B(I) was isolated: this 
phloroglucinol type was previously unknown for the section. Isolated B(I) type compound 
possesses unusual rare structure, thus leaving food for reflection and further studies and 
investigations. 
During the isolation and separation process CPC showed very inspiring results: method 
resulted in numerous diverse sub-fractions, which were almost clear and ready to final stage 
separation on semi-preparative HPLC. It is positively suggested to use CPC for future works 
with PE extracts. Semi-preparative RP-HPLC method with water and MeCN (20:80, MeCN → 
100%) is also noted as a good enough one for isolation of acylphloroglucinols. The herb 
undoubtedly comprises much wider spectrum of phloroglucinol derivatives, ca. 30-40 more 
compounds might be isolated, thus completing the knowledge about its unpolar phenolic 
constituents. 
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3.2 Cell culture experiments 
In order to pharmacologically characterise newly isolated substances from H. triquetrifolium, 
they were tested in MTT assays on neurotoxicity and neuroprotection on HT-22 cells. This 
continues a row of acylphloroglucinols’ neuroprotection studies, conducted on 
Pharmaceutical Biology department of the University of Regensburg (Pitzl et al., 2015). 
3.2.1 General amendments: solvent’s influence on the cells 
Pure DMSO solution for molecular biology (§ 2.2.2) was used to solve the investigated 
substances and to prepare 0.1 M stock solutions (stored in freezer). Straight before 
conducting a single experiment, each stock solution was diluted with growth medium in ratio 
1:2000 in order to prepare a 50 µM stock solution. The latter was then used to produce a 
dilution series 1 µM, 5 µM, 10 µM and 25 µM, which were the investigated concentrations. 
DMSO concentration in each case was, therefore, 0.001%, 0.005%, 0.01% and 0.025% 
respectively. 
In order to evaluate the influence of the solvent on the HT-22 cells, three independent 
successive experiments were performed with DMSO concentrations 0.01%, 0.025% and 
0.05% in growth medium (Fig. 108). Data analysis shows no significant influence of DMSO on 
the cells in its highest used concentration (0.025%) and lower. Therefore, the impact of the 
solvent during the tests may be neglected. 
 
Fig. 108. Impact of DMSO on HT-22 cells. 
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3.2.2 Neurotoxicity and neuroprotection of acylphloroglucinols 
Isolated acylphloroglucinols were tested on neurotoxicity and neuroprotection in vitro (§ 
2.2). 
Desired are low or absence of any toxicity in highest tested concentration (25 µM), as well as 
high neuroprotective potency in lowest tested concentrations (1-5 µM). Neuroprotection 
effect of the investigated compounds should be close to or exceed the one of quercetin 
(positive control). Obtained data results may be observed from Tab. 18. 
Tab. 18. Neurotoxicity and neuroprotection assays for isolated acylphloroglucinols. 
Neurotoxicity assay Neuroprotection assay 
(1) Triquetriborin 
 
 
(2) Triquetrijakobin A 
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(3) Triquetrijakobin B 
 
 
(4) Triquetrireboudin A 
 
 
(5) Triquetrireboudin B 
 
 
(6) Triquetrireboudin C 
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(7) Triquetrikotelin A 
 
 
(9) Triquetriroxettin 
 
 
Control – untreated cells, taken as 100%. 1, 5, 10, 25 µM – concentrations of the investigated compounds. Glu 
– 5 mM glutamate [negative control]. Q – quercetin in DMSO with 5 mM glutamate in growth medium [positive 
control]. In neuroprotection assay all means are expressed as percent to control, i.e. untreated cells, taken as 
100%. 
Data were subjected to one-way ANOVA followed by Dunnett’s multiple comparison post-test using GraphPad 
Prism 5.03 software. Levels of significance are: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
 
3.2.2.1 Evaluation of results and discussion 
All investigated acylphloroglucinols express dose-dependent in-vitro toxicity on HT-22 cells. 
Tested compounds may be divided in two groups. First group unites compounds, which are 
toxic in low concentrations (≥ 5 µM) and their toxicity rises drastically with the rise of the 
concentration (1, 5 and 9). Substances of the second group show almost no influence on the 
cells at ≤ 10 µM, but are significantly toxic at 25 µM (2, 3, 4, 6 and 7). When compared to 
work of Pitzl et al. (Appendix, § 7.2), compounds UR-QS-7, UR-QS-8 and UR-QS-14 may be 
refered to the first group, while UR-QS-2 and UR-QS-4 refer to the second. Furthermore, 
Pitzl et al. has some phloroglucinols which are not toxic for HT-22 cells in concentrations ≤ 25 
µM (UR-QS-1 and UR-QS-12). 
By comparing similar structures and their effect, for example, 7 and 9 – additional isoprene 
rest (lipophilic aliphatic chain) in position 12 seems to make 9 more toxic. In addition, stereo 
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chemistry of various chiral centers is not clear, e.g. positions 4, 6 and 10, which may also 
change the look of the molecule critically and therefore its effects on the cells. Consequently 
the spatial arrangement of atoms plays a key role in substances’ biological effects, when 
comparing 4 and 5. Both compounds possess the same skeleton, but differ in stereo 
chemistry. Their influence on the HT-22 cells is also very diverse. However, 4 and 6 seem to 
be quite similar, and an additional –CH2– group in starter acid of 6 does not play any 
important role in exhibiting the chemical’s toxicity. 
None of the tested compounds exhibit any neuroprotective properties in the model used, 
except for 1. It possesses very slight protective activity at 25 µM. However, 1 is shown to be 
toxic in high concentrations and its protectivity action is apparently overlaid by its 
deleterious effect. 
When compared to the results of (Pitzl et al., 2015) (Appendix, § 7.2), where several 
acylphloroglucinols show protective effects, the structural difference between the 
investigated chemicals should be noted. Most compounds tested by Pitzl et al. exhibit 
neuroprotective effects at ≥ 25 µM, however, at the same time, some of them are toxic for 
HT-22 cells at ≥ 10 µM and their protective effects do not overcome the one of quercetin, as 
positive control. 
Among non-toxic protective compounds are simple monocyclic acylphloroglucinols with long 
aliphatic geranyl chain (UR-QS-1) and two similar bicyclic (5-para-pyrano type, Fig. 16) non-
prenylated chemicals with substituted aromatic started acid (UR-QS-12 and UR-QS-14). 
These compounds differ from those, tested in the course of the present work. And despite 
the fact that substances 7 and 9 are also 5-para-pyrano type acylphloroglucinols, they are 
PPAPs and also possess additional ring and 1 or 2 isoprene chains, which may increase the 
lipophilicity of the molecule. 
Non-prenylated compounds with hydroxylated and/or methoxylated aromatic starter acid 
(UR-QS-12 and UR-QS-14) look very much like flavonoids, for example, quercetin. In this 
case, starter acid aromatic ring may play the role of flavonoid’s “B”-ring. Therefore, these 
substances exhibit their neuroprotective properties most probably in the same way as 
flavonoids. 
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Interesting is to compare the results of toxicity tests of 2 with UR-QS-1. Both compounds 
posess long aliphatic lypophilic side chain, which inter alia may be responsible for non-
toxicity of the substances. 
Tested by Pitzl et al. UR-QS-4 is a 3-ortho-pyrano bicyclic phloroglucinol with intramolecular 
hydrogen bond, compared to 2 and 3. These compounds are the same in being non-toxic at 
≤ 10 µM and slightly toxic or really toxic at ≥ 25 µM. UR-QS-4 however expresses insufficient 
protection effects (< 50%), while 2 and 3 are non-protective at all. Compounds 4 and 6 of the 
same bicyclic 3-ortho-pyrano type express almost the same toxicity as UR-QS-4, but 
protection tests are once again different. Compound 5 differs in its toxicity properties from 
UR-QS-4 most probably because of its odd stereo configuration. 
All in all in-vitro neurotoxicity effects of acylphloroglucinols are very difficult to predict. 
Sometimes the issue is about substituents in aromatic starter acid (UR-QS-7 versus UR-QS-
12) or in stereo configuration (4 versus 5, and probably 7 versus 9 [?]). Good protective 
properties exhibit small mono- or bicyclic compounds either non-prenylated or those, 
possessing a long aliphatic chain. Polyhydroxylated/methoxylated aromatic starter acids play 
a critical role in exhibiting strong protective activity alongside a relative absence of 
neurotoxicity. 
Important is also to note that prenylated acylphloroglucinols are recently proved to exhibit 
significant neuroprotection in vitro (Gao et al., 2016). These assays were however conducted 
on SK-N-SH cells (human neuroblastoma cell line) and not on HT-22 (mouse hippocampal cell 
line). Although the cells types differ, it may be suggested to test the same compounds on SK-
N-SH model to ensure their biological potency character and to compare the results to 
those, obtained on HT-22 cells. 
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3.2.3 Neurotoxicity and neuroprotection of possible precursors 
Current paragraph presents results of neurotoxicity and neuroprotection MTT assays on HT-
22 cells for isolated possible acylphloroglucinol precursors. Graphs may be observed from 
Tab. 19. 
Tab. 19. Neurotoxicity and neuroprotection assays for possible phloroglucinol precursors. 
Neurotoxicity assay Neuroprotection assay 
(11) (+)-Yezo’otogirin C 
 
 
(12) Triquetriirinon A 
 
 
(14) Triquetriirinon C 
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(15) Triquetriirinon D 
 
 
(18) Rutin 
 
 
Control – untreated cells, taken as 100%. 1, 5, 10, 25 µM – concentrations of the investigated compounds. Glu 
– 5 mM glutamate. Q – quercetin in DMSO with 5 mM glutamate in growth medium. In neuroprotection assay 
all means are expressed as percent to control, i.e. untreated cells, taken as 100%. 
Data were subjected to one-way ANOVA followed by Dunnett’s multiple comparison post-test using GraphPad 
Prism 5.03 software. Levels of significance are: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
 
3.2.3.1 Evaluation of results and discussion 
All tested possible phloroglucinol precursors are almost non toxic at ≤ 10 µM, while 25 µM 
might be slightly toxic. Flavonoid rutin (18), as might be expected, shows no toxicity in tested 
concentrations. As well as in acylphloroglucinols, toxicity of their possible precursors is dose-
dependent. None of the investigated compounds exhibit protective activity in Glu-induced 
neurotoxicity assay. 
If comparing tested possible phloroglucinol precursors with tested prenylated 
acylphloroglucinols (§ 3.2.2), the latter possess more complicated structure. Hyperforin 
analogues (Triquetriirinons) are simple monocyclic compounds with two isoprene rests, 
while yezo’otogirin C is tricyclic condensed and rutin is a glycoside between the flavonol 
123 | R e s u l t s  a n d  D i s c u s s i o n  
quercetin and the disaccharide rutinose. These chemicals’ uncomplicated structure might be 
the reason of their neurotoxicity mild expression. 
Despite their low toxicity, precursors, however, do not possess any neuroprotective 
properties on the investigated model. When compared to potent monocyclic 
acylphloroglucinols tested by (Pitzl et al., 2015), the latter differ in aromatic character of the 
main phloroglucinol core, long aliphatic side chain (geranyl) and large number of hydroxyl 
groups. As such, UR-QS-1 tested by Pitzl at el. is not toxic for HT-22 cells at ≤ 25µM, but 
unlike tested possible phloroglucinol precursors it exhibits strong protective effect at 25 µM. 
Apparently for showing fine protective properties, a molecule should posess an aromatic 
main core, long aliphatic lipophilic chain and hydroxylated-methoxylated aromatic starter 
acid (thus reminding the structure of a flavonoid, e.g. quercetin, used as a positive control 
for the tests).  
3.2.4 Conclusion and summary on cell culture experiments 
Prenylated acylphloroglucinols isolated in course of the present work express low to 
moderate toxicity, however, they show no protection effects. Possible phloroglucinol 
analogues isolated during this work were also tested on the same model. They are almost 
non toxic for these cells, but at the same time do not express any neuroprotectivity either. 
When compared to work conducted on Pharmaceutical Biology department of the University 
of Regensburg (Pitzl et al., 2015) before, some structural differences between tested 
substances can be noted. However, a clear distinction between the structure and its 
biological properties is yet very difficult to make. 
Possible is to obtain compounds via organical synthesis, which might structurally be a 
“mean” between the tested non-toxical and efficient protective chemicals. This, however, 
requires a vast list, i. e. database of already tested compounds. 
Advice for the future work includes testing the isolated and/or similar compounds on human 
neuroblastoma SK-N-SH cells. This line was established from metastatic tumor in the bone 
marrow of a 5-year-old girl who had consistently elevated urinary vanillylmandelic acid and 
catecholamine excretion (Helson et al., 1975). Several studies on neuroprotection and 
antioxidation have already been conducted with this model (Bar-Am et al., 2009). 
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Acylphloroglucinols exhibit neuroprotection effects in concentration 10 µM on these cells 
(Gao et al., 2016), while flavonoids, e. g. astragalin, are proved to reduce oxidative stress in 
SK-N-SH model as well (Chung et al., 2016) and can be used as positive control. Interesting is 
to conduct parallel tests of acylphloroglucinols and their possible precursors on both SK-N-
SH and HT-22 cells at the same time, thus comparing two models. 
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4 Summary 
Herbs of the genus Hypericum are widely spread all around the world and are being used in 
both traditional and officinal medicine in most countries and territories of the planet. Native 
to the Mediterranean region Hypericum triquetrifolium TURRA, a close relative to the most 
famous member of the genus Hypericum perforatum L., is well studied on flavonoids and 
especially on its essential oil composition. However, its acylphloroglucinol derivatives 
spectrum was almost unknown. 
The herb’s aerial parts were collected, dried and extracted. With the help of NMR-guided 
fractionation strategy, petroleum ether and methanolic extracts underwent further 
separation by means of various chromatography methods like CPC, Si-gel and RP-18 Flash 
column chromatography, as well as semi-preparative reversed-phase HPLC. Obtained are 
twenty compounds of different structure, including previously unknown prenylated 
acylphloroglucinols of several types, their possible precursors, hyperforin analogues, fatty 
acids and flavonoids. Compounds’ structures were elucidated with 1D- and 2D-NMR 
methods and confirmed with MS. Newly isolated chemicals were characterised by means of 
UV and specific rotation, as well as by CD spectra. 
The spectrum of isolated compounds corresponds with the one, known for other 
representatives of the section, thus confirming taxonomic relationships between species. 
PPAP of type B(I) was also isolated, and this is the first report of such a compound for section 
9 representatives. Biosynthesis of yezo’otogirin C, one of the main constituents of the herbs 
from section 9 was also confirmed: its theoretically proposed precursor was isolated from 
the living plant for the first time from the sub-fraction close to that of the yezo’otogirin C 
itself. 
Isolated in sufficient quantities phloroglucinols were tested on neurotoxicity and 
neuroprotection on HT-22 cells in MTT assays. Neurotoxicity of the tested compounds differs 
from low to moderate, however none of them expresses any neuroprotective properties in 
this model. 
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5 List of abbreviations 
1D – one-dimentional 
12-LOX – 12-lipoxygenase 
2D – two-dimensional 
Å – ångström 
AAR – anisaldehyde reagent in sulfuric acid = derivatized with anisaldehyde/H2SO4 reagent 
Aβ – amyloid-β 
AChE – acetylcholinesterase 
AD – Alzheimer’s disease 
ADP – adenosine diphosphate 
AIF – apoptosis-inducing factor 
ALS – amyotrophic lateral sclerosis 
AMPA – α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ATP – adenosine triphosphate 
BPAPs – bicyclic polyprenylated acylphloroglucinols 
ca. – from Latin circa = “around” = “about” 
cat. no. – catalogue number 
CD – circular dichroism 
CDCl3 – deuterated chloroform 
cGMP – cyclic guanosine monophosphate 
CJD – Creutzfeld-Jakob disease 
CNS – central nervous system 
CoA – coenzyme A 
COSY – correlation spectroscopy 
CPC – centrifugal partition chromatography 
δ – chemical shift, ppm 
DLB – dementia with Lewy bodies 
DMAPP – dimethylallyl pyrophosphate = dimethylallyl diphosphate 
DMEM – Dulbecco’s Modified Eagle Medium 
DMSO – dimethyl sulfoxide 
DNA – deoxyribonucleic acid 
DOXP – 1-deoxy-D-xylulose 5-phosphate  
EDTA – ethylenediaminetetraacetic acid = ethylenediaminetetraacetate 
e.g. – from Latin exempli gratia = “for example” 
et al. – from Latin et alii = and others 
etc. – from Latin et cetera = “and other things” = “and so forth” 
EtOAc – ethyl acetate 
EtOH – ethanol 
EU – European Union 
FCS – fetal calf serum = fetal bovine serum 
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FCS HI – heat-inactivated fetal calf serum 
Fig. – figure 
Glu – glutamate = glutamic acid 
GPP – geranyl diphosphate 
GSH – glutathione 
GTP – guanosine triphosphate 
h – hour, hours 
H. – Hypericum 
HIV – human immunodeficiency virus 
HMBC – heteronuclear multiple-bond correlation spectroscopy 
HPLC – high-performance liquid chromatography 
HSQC – heteronuclear single-quantum correlation spectroscopy 
Hz – hertz 
i.e. – from Latin id est = “in other words” = “which means” 
iNOS – cytokine-inducible nitric oxide synthase 
IPP – isopentenyl pyrophosphate 
IUPAC – International Union of Pure and Applied Chemistry 
J – coupling constant, Hz 
JPND – EU Joint Programme – Neurodegenerative Disease Research 
K – Kelvin 
L – liter 
LC50 – lethal concentration 50 
MAPK – mitogen-activated protein kinase 
ME – methanolic extract 
MeCN – acetonitrile 
MeOH – methanol 
MEP – 2-methylerythritol 4-phosphate 
MHz – megahertz 
MIT – Massachusetts Institute of Technology 
MPAPs – monocyclic prenylated acylphloroglucinols 
MS – mass spectrometry 
MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mult – multiplicity 
m/z – mass-to-charge ratio 
MVA – mevalonic acid 
NADH – nicotinamide adenine dinucleotide 
NADPH – nicotinamide adenine dinucleotide phosphate 
NDs – neurodegenerative diseases = neurodegenerative disorders 
NMDA – N-methyl-D-aspartate 
NMR – nuclear magnetic resonance 
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NOESY – nuclear Overhauser effect spectroscopy 
p.a. – for analysis 
PBS – phosphate buffered saline 
PE – petroleum ether, petroleum ether extract 
PKS – polyketide synthase 
PPAPs – polycyclic prenylated acylphloroglucinols 
ppm – parts per million 
PRC – People’s Republic of China 
PT – prenyltransferase 
Rf – retardation factor = retention factor 
RNS – reactive nitrogen species 
ROS – reactive oxygen species 
RP-18 – reversed-phase octadecyl carbon chain (C18)-bonded silica gel 
rpm – revolutions per minute 
RT – room temperature 
sGC – soluble guanylylcyclase 
SDS – sodium dodecyl sulphate 
Si-gel – silica gel 
subsect. – subsection 
Tab. – table 
TCM – traditional Chinese medicine 
TLC – thin-layer chromatography 
TNF-α – tumor necrosis factor alpha 
tR – retention time 
TRPC6 – transient receptor potential cation channel, subfamily C, member 6 
US – United States [of America] 
USA – United States of America 
UV – ultraviolet 
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7 Appendix 
7.1 Voucher specimens 
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7.2 Work of Sebastian Pitzl on neurotoxicity and neuroprotection 
The following paragraph presents the internal unpublished data, obtained by Mr. Sebastian 
Pitzl during his Master thesis work on Pharmaceutical Biology department of the University 
of Regensburg, Germany. His work on neurotoxicity and neuroprotection on HT-22 cells was 
supervised by Dr. Beata Kling and Prof. Dr. Jörg Heilmann. These data is specified here with 
the kind permission of Mr. Sebastian Pitzl. 
 
7.2.1 Structural formulas of the tested substances 
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7.2.2 Results 
 
Evaluation of neurotoxicity and neuroprotection of UR-QS-8, UR-QS-9, UR-QS-12 und UR-QS-14 
Level of significance: p < 0,05 (*), p < 0,01 (**), p < 0,001 (***), p < 0,0001 (****) 
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Evaluation of neurotoxicity and neuroprotection of UR-QS-8, UR-QS-9, UR-QS-12 und UR-QS-14 
Level of significance: p < 0,05 (*), p < 0,01 (**), p < 0,001 (***), p < 0,0001 (****) 
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7.3 NMR spectra 
1H-NMR (1)  
 
13C-NMR (1) 
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1H-NMR (2)  
 
13C-NMR (2) 
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1H-NMR (3)  
 
13C-NMR (3) 
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1H-NMR (4)  
 
13C-NMR (4) 
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1H-NMR (5)  
 
13C-NMR (5) 
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1H-NMR (6)  
 
13C-NMR (6) 
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1H-NMR (7)  
 
13C-NMR (7) 
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1H-NMR (8)  
 
13C-NMR (8) 
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1H-NMR (9)  
 
13C-NMR (9) 
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1H-NMR (10)  
 
13C-NMR (10) 
 
 
 
161 | A p p e n d i x  
1H-NMR (11)  
 
13C-NMR (11) 
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1H-NMR (12)  
 
13C-NMR (12) 
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1H-NMR (12+13)  
 
13C-NMR (12+13) 
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1H-NMR (14)  
 
13C-NMR (14) 
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1H-NMR (15) 
 
13C-NMR (15) 
 
 
 
